Details of Drug-Metabolizing Enzyme (DME)

General Information of DME (ID: DME0021)
DME Name	Mephenytoin 4-hydroxylase (CYP2C19), Homo sapiens
Synonyms	Fenbendazole monooxygenase (4'-hydroxylating); Cytochrome P450 2C19; Cytochrome P450-11A; Cytochrome P450-254C; CYP2C19; CYPIIC17; CYPIIC19
Gene Name	CYP2C19
UniProt ID	CP2CJ_HUMAN
Gene ID	1557
EC Number	EC: 1.14.14.1 (Click to Show/Hide the Complete EC Tree) Oxidoreductase Oxygen paired donor oxidoreductase Flavin/flavoprotein donor oxidoreductase EC: 1.14.14.1
Lineage	Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Interactome (loading-time for this interactome depdends on the speed of web connection)
Interactions between Microbiome and DME (MICBIO) Jump to Detailed Interactome Data
Interactions between Xenobiotics and DME (XEOTIC) Jump to Detailed Interactome Data
Interactions between Host Protein and DME (HOSPPI) Jump to Detailed Interactome Data

Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME
Sequence	MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP PFYQLCFIPV
Structure	4GQS
Pathway	Arachidonic acid metabolism (hsa00590 )
	Chemical carcinogenesis (hsa05204 )
	Drug metabolism - cytochrome P450 (hsa00982 )
	Linoleic acid metabolism (hsa00591 )
	Metabolic pathways (hsa01100 )
	Serotonergic synapse (hsa04726 )
Function	This enzyme is involved in the metabolism of polyunsaturated fatty acids (PUFA). It catalyzes the hydroxylation of carbon-hydrogen bonds and hydroxylates PUFA specifically at the omega-1 position. Besides, it also catalyzes the epoxidation of double bonds of PUFA and metabolizes plant monoterpenes such as limonene. It is also responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.

Full List of Drug(s) Metabolized by This DME
Drugs Approved by FDA			Click to Show/Hide the Full List of Drugs: 214 Drugs
Thalidomide	Drug Info	Approved	Breast cancer	ICD11: 2C60	[1]
Bupropion	Drug Info	Approved	Nicotine dependence	ICD11: 6C4A	[2]
Tamoxifen citrate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[3]
Idelalisib	Drug Info	Approved	Chronic lymphocytic leukaemia	ICD11: 2A82	[4]
Warfarin sodium	Drug Info	Approved	Atrial fibrillation	ICD11: BC81	[5]
Estradiol acetate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[6]
Estradiol cypionate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[6]
Estradiol valerate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[6]
Estrone	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[7]
Methylphenidate	Drug Info	Approved	Attention deficit hyperactivity disorder	ICD11: 6A05	[8]
Nicotine	Drug Info	Approved	Nicotine dependence	ICD11: 6C4A	[9]
Dronabinol	Drug Info	Approved	Anorexia nervosa	ICD11: 6B80	[10]
Bortezomib	Drug Info	Approved	Breast cancer	ICD11: 2C60	[11]
Diclofenac sodium	Drug Info	Approved	Osteoarthritis	ICD11: FA00	[12]
Hydrocodone	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[13]
Antazoline	Drug Info	Approved	Nasal congestion	ICD11: MD11	[14]
Fospropofol disodium	Drug Info	Approved	Monitored anaesthesia care	ICD11: N.A.	[15]
Montelukast sodium	Drug Info	Approved	Asthma	ICD11: CA23	[16]
Progesterone	Drug Info	Approved	Premature labour	ICD11: JB00	[17]
Almogran	Drug Info	Approved	Migraine	ICD11: 8A80	[18]
Almogran	Drug Info	Approved	Migraine	ICD11: 8A80	[19]
Brivaracetam	Drug Info	Approved	Focal seizure	ICD11: 8A68	[20]
Cannabidiol	Drug Info	Approved	Lennox-Gastaut syndrome	ICD11: 8A62	[21]
Capsaicin	Drug Info	Approved	Herpes zoster	ICD11: 1E91	[22]
Clomipramine hydrochloride	Drug Info	Approved	Obsessive-compulsive disorder	ICD11: 6B20	[23]
Doxazosin	Drug Info	Approved	Essential hypertension	ICD11: BA00	[24]
Ethinyl estradiol	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[25]
Fedratinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[26]
Ifosfamide	Drug Info	Approved	Lung cancer	ICD11: 2C25	[27]
Lapatinib ditosylate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[28]
Terbinafine hydrochloride	Drug Info	Approved	Pityriasis versicolor	ICD11: 1F2D	[29]
Ticlopidine	Drug Info	Approved	Cerebral stroke	ICD11: 8B11	[11]
Tipranavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[30]
Valproic acid	Drug Info	Approved	Epilepsy	ICD11: 8A60	[31]
Almotriptan malate	Drug Info	Approved	Migraine	ICD11: 8A80	[32]
Aprepitant	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[33]
Bupivacaine hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[34]
Clomipramine	Drug Info	Approved	Depression	ICD11: 6A70-6A7Z	[35]
Clomipramine	Drug Info	Approved	Depression	ICD11: 6A70-6A7Z	[23], [35]
Labetalol	Drug Info	Approved	Essential hypertension	ICD11: BA00	[36]
Norethindrone	Drug Info	Approved	Solid tumour/cancer	ICD11: 2A00-2F9Z	[37]
Oxycodone hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[38]
Trabectedin	Drug Info	Approved	Leiomyosarcoma	ICD11: 2B58	[39]
Albendazole	Drug Info	Approved	Giardiasis	ICD11: 1A31	[40]
Clomiphene citrate	Drug Info	Approved	Female infertility	ICD11: GA31	[41]
Dopamine hydrochloride	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[42]
Hydrocodone bitartrate	Drug Info	Approved	Neuropathic pain	ICD11: 8E43	[43]
Meperidine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[44]
Quinine sulfate	Drug Info	Approved	Malaria	ICD11: 1F40	[45]
Teniposide	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[36]
Amoxicillin	Drug Info	Approved	Acute otitis media	ICD11: AB00	[46]
Axitinib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[47]
Cisapride	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[48]
Dextromethorphan hydrobromide	Drug Info	Approved	Atherosclerosis	ICD11: BA80	[49]
Diazepam	Drug Info	Approved	Epilepsy	ICD11: 8A60	[50]
Doxepin hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[51]
Flutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[52]
Formoterol	Drug Info	Approved	Asthma	ICD11: CA23	[53]
Haloperidol decanoate	Drug Info	Approved	Agitation/aggression	ICD11: 6D86	[54]
Lansoprazole	Drug Info	Approved	Duodenal ulcer	ICD11: DA63	[55]
Levonorgestrel	Drug Info	Approved	Menorrhagia	ICD11: GA20	[56]
Lorcaserin	Drug Info	Approved	Obesity	ICD11: 5B81	[57]
Macitentan	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[58]
Norethindrone acetate	Drug Info	Approved	Menorrhagia	ICD11: GA20	[36]
Pomalidomide	Drug Info	Approved	Breast cancer	ICD11: 2C60	[59]
Propranolol hydrochloride	Drug Info	Approved	Migraine	ICD11: 8A80	[60]
Verapamil hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[61]
Amitriptyline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[62]
Artemether	Drug Info	Approved	Malaria	ICD11: 1F40	[63]
Atomoxetine hydrochloride	Drug Info	Approved	Attention deficit hyperactivity disorder	ICD11: 6A05	[64]
Benzatropine	Drug Info	Approved	Agitation/aggression	ICD11: 6D86	[65]
Bromfenac	Drug Info	Approved	Cataract	ICD11: 9B10	[66]
Carbamazepine	Drug Info	Approved	Epilepsy	ICD11: 8A60	[67]
Cenobamate	Drug Info	Approved	Focal seizure	ICD11: 8A68	[68]
Clobazam	Drug Info	Approved	Lennox-Gastaut syndrome	ICD11: 8A62	[69]
Cyclophosphamide	Drug Info	Approved	Multiple myeloma	ICD11: 2A83	[3]
Diltiazem hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[70]
Felbamate	Drug Info	Approved	Epilepsy	ICD11: 8A60	[50]
Fluoxetine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[71]
Ibuprofen	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[50]
Imipramine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[72]
Indomethacin	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[11]
Leflunomide	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[73]
Lesinurad	Drug Info	Approved	Uncontrolled gout	ICD11: FA25	[74]
Metoprolol succinate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[50]
Metoprolol tartrate	Drug Info	Approved	Angina pectoris	ICD11: BA40	[75]
Nilutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[76]
Oxymetazoline	Drug Info	Approved	Erythema multiforme	ICD11: EB12	[77]
Phenytoin	Drug Info	Approved	Epilepsy	ICD11: 8A60	[50]
Prazepam	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[78]
Promazine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[79]
Rilpivirine hydrochloride	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[80]
Simvastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[81]
Suvorexant	Drug Info	Approved	Insomnia	ICD11: 7A00	[82]
Tapentadol	Drug Info	Approved	Neuropathic pain	ICD11: 8E43	[83]
Tofacitinib citrate	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[84]
Zanubrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[85]
Zolpidem tartrate	Drug Info	Approved	Insomnia	ICD11: 7A00	[86]
Amiodarone hydrochloride	Drug Info	Approved	Ventricular tachyarrhythmia	ICD11: BC71	[87]
Aspirin	Drug Info	Approved	Myocardial infarction	ICD11: BA41	[88]
Azelastine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[89]
Bedaquiline fumarate	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[90], [91]
Buprenorphine hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[92]
Chlorpropamide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[93]
Citalopram hydrobromide	Drug Info	Approved	Depression	ICD11: 6A71	[94]
Clarithromycin	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[95]
Clozapine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[96]
Diphenhydramine	Drug Info	Approved	Meniere disease	ICD11: AB31	[11]
Esomeprazole	Drug Info	Approved	Duodenal ulcer	ICD11: DA63	[97]
Etravirine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[98]
Fosphenytoin sodium	Drug Info	Approved	Epilepsy	ICD11: 8A60	[99]
Glipizide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[100]
Loxapine succinate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[101]
Nalbuphine	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[102]
Omeprazole	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[11]
Ospemifene	Drug Info	Approved	Dyspareunia	ICD11: GA12	[103]
Paroxetine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[104]
Pentobarbital	Drug Info	Approved	Insomnia	ICD11: 7A00	[105]
Perphenazine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[106]
Prochlorperazine	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[107]
Propofol	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[108]
Quetiapine fumarate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[109]
Rabeprazole sodium	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[110]
Sumatriptan	Drug Info	Approved	Migraine	ICD11: 8A80	[111]
Tasimelteon	Drug Info	Approved	Insomnia	ICD11: 7A00	[112]
Testosterone undecanoate	Drug Info	Approved	Hypogonadism	ICD11: 5A61	[17]
Thioridazine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[113]
Triclosan	Drug Info	Approved	Malaria	ICD11: 1F40-1F45	[114]
Venlafaxine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[115]
Vilazodone hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[116]
Vortioxetine hydrobromide	Drug Info	Approved	Depression	ICD11: 6A71	[117]
Apixaban	Drug Info	Approved	Deep vein thrombosis	ICD11: BD71	[118]
Benzocaine	Drug Info	Approved	Anaesthesia	ICD11: 9A76-9A78	[119]
Desloratadine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[120]
Dexlansoprazole	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[121]
Fedratinib hydrochloride	Drug Info	Approved	Myelofibrosis	ICD11: 2A22	[122]
Lenvatinib	Drug Info	Approved	Thyroid cancer	ICD11: 2D10	[123]
Levomilnacipran	Drug Info	Approved	Depression	ICD11: 6A71	[124]
Lovastatin	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[81]
Methadone	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[125]
Midodrine	Drug Info	Approved	Orthostatic hypotension	ICD11: BA21	[126]
Nelfinavir mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[127]
Pantoprazole sodium	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[128]
Phenelzine	Drug Info	Approved	Depression	ICD11: 6A71	[129]
Phenobarbital	Drug Info	Approved	Epilepsy	ICD11: 8A60	[130]
Ranitidine	Drug Info	Approved	Peptic ulcer	ICD11: DA61	[131]
Sulfadiazine	Drug Info	Approved	Toxoplasmosis	ICD11: 1F57	[132]
Tapinarof	Drug Info	Approved	Discovery agent	ICD: N.A.	[133]
Thiopental	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[134]
Timolol maleate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[135]
Tolbutamide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[136]
Tolterodine tartrate	Drug Info	Approved	Overactive bladder	ICD11: GC50	[137]
Troglitazone	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[138]
Voriconazole	Drug Info	Approved	Candidiasis	ICD11: 1F23	[139]
Zidovudine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[50]
Acebutolol	Drug Info	Approved	Essential hypertension	ICD11: BA00	[140]
Ambrisentan	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[141]
Arformoterol	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[142]
Azilsartan	Drug Info	Approved	Hypertension	ICD11: BA00-BA04	[143], [144]
Carisoprodol	Drug Info	Approved	Depression	ICD11: 6A71	[145]
Chloramphenicol	Drug Info	Approved	Conjunctivitis	ICD11: 9A60	[146]
Cilostazol	Drug Info	Approved	Arteriosclerosis obliterans	ICD11: BD40	[147]
Clopidogrel bisulfate	Drug Info	Approved	Acute coronary syndrome	ICD11: BA4Z	[148]
Dapsone	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[149]
Dydrogesterone	Drug Info	Approved	Menorrhagia	ICD11: GA20	[150]
Eletriptan hydrobromide	Drug Info	Approved	Migraine	ICD11: 8A80	[151]
Escitalopram	Drug Info	Approved	Depression	ICD11: 6A71	[152]
Flibanserin	Drug Info	Approved	Inhibited sexual desire	ICD11: HA00	[153]
Iclaprim	Drug Info	Approved	Methicillin-resistant staphylococcus infection	ICD11: 1D01	[154]
Lacosamide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[155]
Lomitapide mesylate	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[156]
Loratadine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[157]
Mephenytoin	Drug Info	Approved	Epilepsy	ICD11: 8A60	[158]
Pentamidine isethionate	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[159]
Prasugrel hydrochloride	Drug Info	Approved	Acute coronary syndrome	ICD11: BA4Z	[160]
Primidone	Drug Info	Approved	Epilepsy	ICD11: 8A60	[161]
Quazepam	Drug Info	Approved	Insomnia	ICD11: 7A00	[162]
Rosuvastatin	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[11]
Selegiline	Drug Info	Approved	Major depressive disorder	ICD11: 6A70-6A7Z	[163]
Selegiline hydrochloride	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[163]
Sertraline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[164]
Sildenafil citrate	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[165]
Stiripentol	Drug Info	Approved	Epilepsy	ICD11: 8A60	[166]
Temazepam	Drug Info	Approved	Insomnia	ICD11: 7A00	[167]
Triclabendazole	Drug Info	Approved	Fascioliasis	ICD11: 1F82	[168]
Trimipramine	Drug Info	Approved	Depression	ICD11: 6A71	[169]
Voxelotor	Drug Info	Approved	Sickle-cell anaemia	ICD11: 3A51	[122]
Zonisamide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[170]
Chloroquine	Drug Info	Approved	Malaria	ICD11: 1F40	[171]
Chlorproguanil	Drug Info	Approved	Malaria	ICD11: 1F40-1F45	[172]
Desipramine	Drug Info	Approved	Attention deficit hyperactivity disorder	ICD11: 6A05	[173]
Enasidenib	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[174]
Encorafenib	Drug Info	Approved	Melanoma	ICD11: 2C30	[175]
Enfuvirtide	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[176]
Famotidine	Drug Info	Approved	Peptic ulcer	ICD11: DA61	[177]
Ibudilast	Drug Info	Approved	Castleman's disease	ICD11: 4B2Y	[178]
Lorlatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[179]
Nebivolol hydrochloride	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[180]
Nortriptyline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[181]
Praziquantel	Drug Info	Approved	Schistosomiasis	ICD11: 1F86	[182]
Rifampicin	Drug Info	Approved	Osteoporosis	ICD11: FB83	[183]
Romidepsin	Drug Info	Approved	Cutaneous T-cell lymphoma	ICD11: 2B01	[184]
Testosterone cypionate	Drug Info	Approved	Testosterone deficiency	ICD11: 5A81	[17]
Testosterone enanthate	Drug Info	Approved	Testosterone deficiency	ICD11: 5A81	[17]
Tilidine	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[185]
Trimethadione	Drug Info	Approved	Epilepsy	ICD11: 8A60	[186]
Meprobamate	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[145]
Methsuximide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[172]
Oxiconazole	Drug Info	Approved	Dermatophytosis	ICD11: 1F28	[187]
Podophyllotoxin	Drug Info	Approved	Anogenital warts	ICD11: 1A95	[188]
Ramelteon	Drug Info	Approved	Insomnia	ICD11: 7A00	[189]
Testosterone	Drug Info	Approved	Osteoporosis	ICD11: FB83	[190]
Berberine	Drug Info	Phase 4	Discovery agent	ICD: N.A.	[192]
Neupro	Drug Info	Phase 4	Restless legs syndrome	ICD11: 7A80	[196]
Drugs in Phase 4 Clinical Trial			Click to Show/Hide the Full List of Drugs: 31 Drugs
Lumiracoxib	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[191]
Desogestrel	Drug Info	Phase 4	Female pelvic pain	ICD11: GA34	[193]
Glibenclamide	Drug Info	Phase 4	Diabetes mellitus	ICD11: 5A10	[11]
Ketobemidone	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[194]
Naftopidil	Drug Info	Phase 4	Prostatic hyperplasia	ICD11: GA90	[195]
Piperaquine	Drug Info	Phase 4	Malaria	ICD11: 1F40	[197]
Melatonin	Drug Info	Phase 4	Foetal growth restriction	ICD11: KA20	[198]
Mianserin	Drug Info	Phase 4	Depression	ICD11: 6A71	[199]
Vonoprazan	Drug Info	Phase 4	Gastro-oesophageal reflux disease	ICD11: DA22	[200]
Vonoprazan	Drug Info	Phase 4	Gastro-oesophageal reflux disease	ICD11: DA22	[201]
Zotepine	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[202]
Barbital	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[203]
Idebenone	Drug Info	Phase 4	Mitochondrial myopathy	ICD11: 8C73	[204]
Phenacetin	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[205]
Tienilic acid	Drug Info	Phase 4	Congestive heart failure	ICD11: BD10	[11]
Aminophenazone	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[206]
Clotiazepam	Drug Info	Phase 4	Anxiety disorder	ICD11: 6B00	[207]
Flunitrazepam	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[208]
Gliclazide	Drug Info	Phase 4	Diabetes mellitus	ICD11: 5A10	[209]
Lynestrenol	Drug Info	Phase 4	Transsexualism	ICD11: HA60	[37]
Perazine	Drug Info	Phase 4	Cerebrovascular dementia	ICD11: 6D81	[210]
Buflomedil	Drug Info	Phase 4	Arterial occlusive disease	ICD11: BD4Z	[50]
Dexibuprofen	Drug Info	Phase 4	Osteoarthritis	ICD11: FA00	[211]
Etizolam	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[212]
Ketazolam	Drug Info	Phase 4	Anxiety disorder	ICD11: 6B00	[213]
Lofexidine	Drug Info	Phase 4	Opiate dependence	ICD11: 6C43	[214]
Milnacipran	Drug Info	Phase 4	Asperger syndrome	ICD11: 6A02	[215]
Milnacipran	Drug Info	Phase 4	Asperger syndrome	ICD11: 6A02	[216]
Proguanil	Drug Info	Phase 4	Malaria	ICD11: 1F40	[217]
Glucosamine	Drug Info	Phase 4	Osteoarthritis	ICD11: FA00	[218]
Benzethonium	Drug Info	Phase 4	Methicillin-resistant staphylococcus infection	ICD11: 1D01	[65]
Drugs in Phase 3 Clinical Trial			Click to Show/Hide the Full List of Drugs: 22 Drugs
PF-04965842	Drug Info	Phase 3	Atopic dermatitis	ICD11: EA80	[219]
E-3A	Drug Info	Phase 3	Turner syndrome	ICD11: LD50	[220]
Fruquintinib	Drug Info	Phase 3	Solid tumour/cancer	ICD11: 2A00-2F9Z	[221]
Selumetinib	Drug Info	Phase 3	Neurofibromatosis	ICD11: LD2D	[222], [223]
PG-490	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[224]
BMS-298585	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[225]
BMS-650032	Drug Info	Phase 3	Viral hepatitis	ICD11: 1E51	[226]
Tivantinib	Drug Info	Phase 3	Solid tumour/cancer	ICD11: 2A00-2F9Z	[227]
Mavacamten	Drug Info	Phase 3	Hypertrophic cardiomyopathy	ICD11: BC43	[228]
RO-111163	Drug Info	Phase 3	Hypersalivation	ICD11: DA04	[229]
GW-1000	Drug Info	Phase 3	Cerebral vasospasm	ICD11: BA85	[230]
LY-450139	Drug Info	Phase 3	Alzheimer disease	ICD11: 8A20	[231]
Fenfluramine	Drug Info	Phase 3	Dravet syndrome	ICD11: 8A61-8A6Z	[232]
INCB-024360	Drug Info	Phase 3	Renal cell carcinoma	ICD11: 2C90	[233]
BAY-8697661	Drug Info	Phase 3	Hepatocellular carcinoma	ICD11: 2C12	[234]
Ganaxolone	Drug Info	Phase 3	Complex partial seizure	ICD11: 8A61-8A6Z	[235]
JNJ-54135419	Drug Info	Phase 3	Depression	ICD11: 6A71	[236]
PT2977	Drug Info	Phase 3	Renal cell carcinoma	ICD11: 2C90	[237]
WY-1485	Drug Info	Phase 3	Haemorrhagic stroke	ICD11: 8B20	[50]
Ag-221	Drug Info	Phase 3	Acute myelogenous leukaemia	ICD11: 2A41	[238]
CYT-387	Drug Info	Phase 3	Myelofibrosis	ICD11: 2A22	[239]
Palovarotene	Drug Info	Phase 3	Fibrodysplasia ossificans progressiva	ICD11: FB31	[240]
Drugs in Phase 2 Clinical Trial			Click to Show/Hide the Full List of Drugs: 24 Drugs
Fexinidazole	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1D51-1F53	[241], [242]
Fexinidazole	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1D51-1F53	[242]
HOE-239	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1F51	[242]
PF-06463922	Drug Info	Phase 2	Lung cancer	ICD11: 2C25	[243]
LIK-066	Drug Info	Phase 2	Heart failure	ICD11: BD10-BD1Z	[244]
SQ-109	Drug Info	Phase 2	Pulmonary tuberculosis	ICD11: 1B10	[245]
PT2385	Drug Info	Phase 2	Von hippel-lindau disease	ICD11: 5A75	[246]
Remogliflozin etabonate	Drug Info	Phase 2	Type-1/2 diabetes	ICD11: 5A10-5A11	[247]
S-777469	Drug Info	Phase 2	Atopic dermatitis	ICD11: EA80	[248]
SSR-97193	Drug Info	Phase 2	Malaria	ICD11: 1F40	[249]
HE-3235	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[250]
HP-184	Drug Info	Phase 2	Multiple sclerosis	ICD11: 8A40	[251]
(Z)-endoxifen	Drug Info	Phase 2	Breast cancer	ICD11: 2C60-2C6Y	[252]
AV-650	Drug Info	Phase 2	Cerebral vasospasm	ICD11: BA85	[253]
Ladostigil	Drug Info	Phase 2	Alzheimer disease	ICD11: 8A20	[254]
AS-703026	Drug Info	Phase 2	Mantle cell lymphoma	ICD11: 2A85	[255]
Dextofisopam	Drug Info	Phase 2	Irritable bowel syndrome	ICD11: DD91	[256]
HPPH	Drug Info	Phase 2	Lung cancer	ICD11: 2C25	[257]
JI-101	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[258]
Verubulin	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[259]
E-7070	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[260]
PF-04937319	Drug Info	Phase 2	Type-2 diabetes	ICD11: 5A11	[261]
PTC299	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[262]
TAK-906	Drug Info	Phase 2	Gastroparesis	ICD11: DA41	[263]
Drugs in Phase 1 Clinical Trial			Click to Show/Hide the Full List of Drugs: 10 Drugs
CB-3304	Drug Info	Phase 1/2	Chronic lymphocytic leukaemia	ICD11: 2A82	[264]
TRV-130	Drug Info	Phase 1/2	Hypothyroidism	ICD11: 5A00	[265]
GTPL7557	Drug Info	Phase 1/2	Schizophrenia	ICD11: 6A20	[266]
AST-1306	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[267]
BE-14348A	Drug Info	Phase 1	Viral hepatitis	ICD11: 1E51	[268]
H3B-6545	Drug Info	Phase 1	Breast cancer	ICD11: 2C60	[269]
Alvespimycin hydrochloride	Drug Info	Phase 1	Ovarian cancer	ICD11: 2C73	[270]
GDC-0623	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[271]
G-23350	Drug Info	Phase 1	Venous thromboembolism	ICD11: BD72	[11]
ITX-5061	Drug Info	Phase 1	Human immunodeficiency virus infection	ICD11: 1C60	[272]
Discontinued/withdrawn Drugs			Click to Show/Hide the Full List of Drugs: 15 Drugs
Almokalant	Drug Info	Discontinued in Phase 3	Cardiac arrhythmias	ICD11: BC9Z	[273]
KRP-297	Drug Info	Discontinued in Phase 2	Hypertriglyceridaemia	ICD11: 5C80	[274]
AZD0328	Drug Info	Discontinued in Phase 2	Alzheimer disease	ICD11: 8A20	[275]
YM-992	Drug Info	Discontinued in Phase 2	Depression	ICD11: 6A70-6A7Z	[276]
BMS-181168	Drug Info	Discontinued in Phase 2	Cognitive impairment	ICD11: 6D71	[277]
SINOMENINE	Drug Info	Discontinued in Phase 2	Rheumatoid arthritis	ICD11: FA20	[278]
AZD0837	Drug Info	Discontinued in Phase 2	Atrial fibrillation	ICD11: BC81	[279]
E2101	Drug Info	Discontinued in Phase 1	Dyskinesia	ICD11: 8A02	[280]
CAM-2028	Drug Info	Discontinued	Acute nasopharyngitis	ICD11: CA00	[218]
Nomifensine	Drug Info	Discontinued	Depression	ICD11: 6A71	[281]
ML-3000	Drug Info	Discontinued	Osteoarthritis	ICD11: FA00	[11]
ABT-001	Drug Info	Discontinued	Asthma	ICD11: CA23	[282]
DEA-2250	Drug Info	Discontinued	Epilepsy	ICD11: 8A60	[283]
GW-873140	Drug Info	Discontinued	Human immunodeficiency virus infection	ICD11: 1C60	[284]
INN-00835	Drug Info	Discontinued	Depression	ICD11: 6A71	[285]
Preclinical/investigative Agents			Click to Show/Hide the Full List of Drugs: 10 Drugs
EPX-100	Drug Info	Preclinical	Dravet syndrome	ICD11: 8A61	[286]
VA-10872	Drug Info	Preclinical	Anaesthesia	ICD11: 8E22	[287]
Bufuralol	Drug Info	Investigative	Cardiac arrhythmia	ICD11: BC65	[288]
Adinazolam	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[289]
Bromazepam	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[290]
Medazepam	Drug Info	Investigative	Discovery agent	ICD: N.A.	[291]
Antipyrine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[292]
Linalool	Drug Info	Investigative	Colon cancer	ICD11: 2B90	[293], [294], [295]
Cyamemazine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[296], [297]
Nordazepam	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[298]

Full List of Metabolic Reactions (MR) Catalyzed by This DME

MR ID	Reactant	Product	MR Type	Source Drug	REF
MR010130	(+)-JQ1	(+)-JQ1 Metabolite M1	Unclear - Unclear	(+)-JQ1	[299]
MR010136	(+)-JQ1	(+)-JQ1 Metabolite M7	Unclear - Unclear	(+)-JQ1	[299]
MR004533	ABT-001	ABT-001 Metabolite M-	Other reaction - Methylhydroxylation	ABT-001	[282], [300]
MR003124	Acebutolol	N-hydroxy acetolol	Oxidation - Hydroxylation	Acebutolol	[301]
MR002798	Adinazolam	Desmethyladinazolam	Oxidation - N-Demethylation	Adinazolam	[289]
MR000103	Agomelatine	Agomelatine metabolite M5	Oxidation - Demethylation	Agomelatine	[302]
MR008995	Almogran	N-desmethylalmotriptan	Oxidation - N-demethylation	Almogran	[18]
MR009416	Almokalant	Almokalant Metabolite M13	Oxidation - Sulfoxidation	Almokalant	[273]
MR009417	Almokalant	Almokalant Metabolite M16	Unclear - Unclear	Almokalant	[273]
MR009419	Almokalant	Almokalant Metabolite M3	Unclear - Unclear	Almokalant	[273]
MR000155	Almotriptan malate	LAS 31612	Oxidation - N-Demethylation	Almotriptan malate	[32], [303]
MR009849	Ambrisentan	4-hydroxymethyl?ambrisentan	Oxidation - Oxidation	Ambrisentan	[304], [305]
MR000169	Aminophenazone	4-(Dimethylamino)-5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one	Oxidation - N-Dealkylation	Aminophenazone	[75]
MR009854	Amitriptyline hydrochloride	Nortriptyline	Unclear - Unclear	Amitriptyline hydrochloride	[306], [307]
MR007486	Antipyrine	Norantipyrine	Unclear - Unclear	Antipyrine	[11]
MR000248	Apixaban	Apixaban M2 metabolite	Oxidation - O-Demethylation	Apixaban	[118], [308]
MR000249	Apixaban	Apixaban M4/7 metabolite	Oxidation - Hydroxylation	Apixaban	[118], [308]
MR002970	Aprepitant	5-({[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}methyl)-2,3-dihydro-1H-1,2,4-triazol-3-one	Oxidation - O-Dealkylation	Aprepitant	[33], [309]
MR002971	Aprepitant	(2R)-2-(4-fluorophenyl)-2-{[(5-oxo-2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]amino}acetic acid	Oxidation - O-Dealkylation	Aprepitant	[33], [309]
MR002969	Aprepitant	(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine	Oxidation - N-Dealkylation	Aprepitant	[33], [309]
MR002972	Aprepitant	5-oxo-1,4-dihydro-1,2,4-triazole-3-carbaldehyde	Oxidation - N-Dealkylation	Aprepitant	[33], [309]
MR002973	Aprepitant	1-[3,5-bis(trifluoromethyl)phenyl]ethanone	Oxidation - N-Demethylation	Aprepitant	[33], [309]
MR002974	Aprepitant	5-{[(2S,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-2,4-dihydro-1,2,4-triazol-3-one	Oxidation - N-Demethylation	Aprepitant	[33], [309]
MR012560	Arecaidine	N-methylnipecotic acid	Unclear - Unclear	Arecoline	[310]
MR013473	Arformoterol	O-Desmethylarformoterol	Oxidation - O-dealkylation	Arformoterol	[311], [312], [313]
MR000298	Artemether	Dihydroartemisinin	Oxidation - Oxidation	Artemether	[314]
MR007272	AS-703026	AS-703026 M445	Unclear - Unclear	AS-703026	[255]
MR009785	AST-1306	Allitinib M1	Oxidation - O-dealkylation	AST-1306	[267]
MR009868	Atomoxetine hydrochloride	N-desmethylatomoxetine	Unclear - Unclear	Atomoxetine hydrochloride	[64]
MR007277	AV-650	AV-650 M1	Unclear - Unclear	AV-650	[253]
MR009891	Axitinib	Axitinib Metabolite M14	Unclear - Unclear	axitinib	[315]
MR009885	Axitinib	Axitinib Metabolite M12	Unclear - Unclear	axitinib	[315]
MR009889	Axitinib	Axitinib Metabolite M8b	Unclear - Unclear	axitinib	[315]
MR009369	AZD0328	AZD0328 Metabolite M6	Oxidation - N-oxidation	AZD0328	[275]
MR011862	AZD0837	AR-H069927	Oxidation - Oxidation	AZD0837	[279]
MR003839	BE-14348A	Eriodictyol	Oxidation - Hydrolyzationn	BE-14348A	[268]
MR006029	Bedaquiline fumarate	N-desmethyl BDQ (M1)	Oxidation - N-demethylation	Bedaquiline fumarate	[90], [91]
MR008758	Benzocaine	Benzocaine hydroxylamine	Oxidation - N-hydroxylation	Benzocaine	[119]
MR013779	Berberine	Demethyleneberberine	Oxidation - Demethylenation	Berberine	[316], [192]
MR011144	BMS-201038	Lomitapide Metabolite M1	Oxidation - N-dealkylation	BMS-201038	[317]
MR000381	BMS-298585	BMS-298585 metabolite M10	Unclear - Unclear	BMS-298585	[225], [318]
MR000382	BMS-298585	BMS-298585 metabolite M11	Unclear - Unclear	BMS-298585	[225], [318]
MR000411	Bortezomib	Bortezomib metabolite M23	Unclear - Unclear	Bortezomib	[11]
MR000412	Bortezomib	Bortezomib metabolite M24	Unclear - Unclear	Bortezomib	[11]
MR000409	Bortezomib	Bortezomib metabolite M2	Oxidation - Oxidation; Deboronation	Bortezomib	[11]
MR000408	Bortezomib	Bortezomib metabolite M1	Oxidation - Oxidative Deboronation	Bortezomib	[11]
MR000416	Bosentan	Bosentan metabolite Ro 47-8634	Oxidation - O-Demethylation	Bosentan	[11]
MR000417	Bosentan	Bosentan metabolite Ro 48-5033	Oxidation - Methyl-Hydroxylation	Bosentan	[11]
MR002552	Brivaracetam	Brivaracetam metabolite M1b	Oxidation - Hydroxylation	Brivaracetam	[20]
MR000458	Bromfenac indolinone	Bromfenac metabolite M3	Unclear - Unclear	Bromfenac	[66], [319]
MR007580	Bufuralol	Unclear	Unclear - Unclear	Bufuralol	[288]
MR000481	Bupivacaine hydrochloride	N-desbutylbupivacaine	Unclear - Unclear	Bupivacaine hydrochloride	[320]
MR000513	Bupropion	S-hydroxybupropion	Oxidation - Hydroxylation	Bupropion	[2]
MR000513	Bupropion	R-hydroxybupropion	Oxidation - Hydroxylation	Bupropion	[2]
MR000514	Bupropion	S-4'-hydroxybupropion	Oxidation - Hydroxylation	Bupropion	[2]
MR000515	Bupropion	R-4'-hydroxybupropion	Oxidation - Hydroxylation	Bupropion	[2]
MR000520	Bupropion	(2R)-2-(tert-butylamino)-1-(3-chlorophenyl)-3-hydroxypropan-1-one	Oxidation - Hydroxylation	Bupropion	[2]
MR000505	R,R-threohydrobupropion	R,R-threo-4'-hydroxy-hydrobupropion	Oxidation - 4'-Hydroxylation	Bupropion	[2]
MR000509	R,S-erythrohydrobupropion	R,S-erythro-4'-hydroxy-hydrobupropion	Oxidation - 4'-Hydroxylation	Bupropion	[2]
MR000512	S,R-erythrohydrobupropion	S,R-erythro-4'-hydroxy-hydrobupropion	Oxidation - 4'-Hydroxylation	Bupropion	[2]
MR000507	S,S-threohydrobupropion	S,S-threo-4'-hydroxy-hydrobupropion	Oxidation - 4'-Hydroxylation	Bupropion	[2]
MR002512	Cannabidiol	7-hydroxy-cannabidiol	Oxidation - Hydroxylation	Cannabidiol	[21]
MR002818	Capsaicin	Capsaicin metabolite M1	Oxidation - Dehydrogenation	Capsaicin	[22]
MR002819	Capsaicin	Capsaicin metabolite M2	Oxidation - Omega-Hydroxylation	Capsaicin	[22]
MR002820	Capsaicin	Capsaicin metabolite M3	Oxidation - Omega-1-Hydroxylation	Capsaicin	[22]
MR002821	Capsaicin	Capsaicin metabolite M4	Oxidation - Dehydrogenation	Capsaicin	[22]
MR002822	Capsaicin	Capsaicin metabolite M5M7	Oxidation - Hydroxylation	Capsaicin	[22]
MR002823	Capsaicin	Capsaicin metabolite M6	Oxidation - O-Dehydrogenation	Capsaicin	[22]
MR002824	Capsaicin	Capsaicin metabolite M8	Oxidation - N-Dehydrogenation; Oxygenation	Capsaicin	[22]
MR002825	Capsaicin	Capsaicin metabolite M9	Oxidation - N-Dehydrogenation	Capsaicin	[22]
MR002586	3-hydroxycarbamazepine	2,3-Dihydroxycarbamazepine	Unclear - Unclear	Carbamazepine	[67]
MR002828	Carisoprodol	Meprobamate	Oxidation - N-dealkylation	Carisoprodol	[321]
MR006088	CB-3304	Hydroxylated metabolite	Oxidation - Hydrolyzationn	CB-3304	[264]
MR006089	CB-3304	Hydroxylated metabolite	Oxidation - Hydrolyzationn	CB-3304	[264]
MR000624	Chloramphenicol	Desmethylcerivastatin	Unclear - Unclear	Chloramphenicol	[146]
MR000625	Chloramphenicol	D-threo-2-amino-1-(p-nitrophenyl)-1,3-propanediol	Unclear - Unclear	Chloramphenicol	[146]
MR000650	Chlorpropamide	2-OH-chlorpropamide	Oxidation - Hydroxylation	Chlorpropamide	[11]
MR000648	Chlorpropamide	2-hydroxychlorpropamide	Oxidation - 2-Hydroxylation	Chlorpropamide	[11]
MR000658	Cilostazol	OPC-13213	Unclear - Unclear	Cilostazol	[322], [323]
MR006517	Citalopram hydrobromide	Demethylcitalopram	Oxidation - N-demethylation	Citalopram hydrobromide	[324], [325]
MR006520	Citalopram propionaldehyde	Citalopram propionic acid	Oxidation - Oxidationn	Citalopram hydrobromide	[325]
MR006520	Citalopram propionaldehyde	Citalopram propionic acid	Oxidation - Oxidationn	Citalopram hydrobromide	[325]
MR006520	Citalopram propionaldehyde	Citalopram propionic acid	Oxidation - Oxidationn	Citalopram hydrobromide	[325]
MR006541	Clobazam	Clobazam Metabolite M9	Unclear - Unclear	Clobazam	[326], [327]
MR006546	Clobazam	Clobazam Metabolite M7	Unclear - Unclear	Clobazam	[326]
MR006547	Clobazam Metabolite M7	Clobazam Metabolite M5	Unclear - Unclear	Clobazam	[326]
MR006544	Clobazam Metabolite M9	Clobazam Metabolite M5	Unclear - Unclear	Clobazam	[326]
MR008660	(E)-4-OH-CLOM	(E)-4-OH-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[41]
MR008656	Clomiphene citrate	(E)-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[41]
MR009006	8-hydroxyclomipramine	8-hydroxydesmethyl clomipramine	Unclear - Unclear	Clomipramine	[328], [35]
MR009009	Clomipramine	Desmethylclomipramine	Oxidation - N-demethylation	Clomipramine	[328]
MR006567	Clomipramine hydrochloride	Desmethylclomipramine	Oxidation - N-demethylation	Clomipramine hydrochloride	[329], [330]
MR006592	2-Oxoclopidogrel	Active Metabolite of Clopidogrel	spontaneous - spontaneous	Clopidogrel bisulfate	[11]
MR006591	Clopidogrel bisulfate	2-Oxoclopidogrel	Oxidation - Oxidationn	Clopidogrel bisulfate	[11]
MR006006	Clotiazepam	Unclear	Unclear - Unclear	Clotiazepam	[207]
MR002835	Clozapine	N-desmethylclozapine	Oxidation - N-Demethylation	Clozapine	[11]
MR005317	Cyamemazine	N-desmethyl cyamemazine	Oxidation - N-demethylation	Cyamemazine	[296], [297]
MR012897	Cyclobenzaprine	4-Hydroxycyclophosphamide	Oxidation - 4-hydroxylation	Cyclobenzaprine	[331], [11]
MR002839	Dapagliflozin	Dapagliflozin BMS-511926	Oxidation - O-Deethylation	Dapagliflozin	[332]
MR002840	Dapagliflozin	Dapagliflozin BMS-639432	Oxidation - Hydroxylation	Dapagliflozin	[332]
MR005954	Mephobarbital	4-hydroxymephobarbital	Unclear - Unclear	DEA-2250	[333]
MR000770	Desloratadine	5-hydroxydesloratadine	Oxidation - Hydroxylation	Desloratadine	[120]
MR000771	Desloratadine	6-hydroxydesloratadine	Oxidation - Hydroxylation	Desloratadine	[120]
MR007087	Desogestrel	3alpha-OH-desogestrel	Oxidation - Hydrolyzationn	Desogestrel	[11]
MR007090	Desogestrel	3beta-OH-desogestrel	Oxidation - Hydrolyzationn	Desogestrel	[11]
MR000795	Dexlansoprazole	5-hydroxy dexlansoprazole	Oxidation - 5-Hydroxylation	Dexlansoprazole	[334]
MR012620	Dextofisopam	Dextofisopam Metabolite M3	Unclear - Unclear	Dextofisopam	[256]
MR012619	Dextofisopam Metabolite M1	Dextofisopam Metabolite M5	Unclear - Unclear	Dextofisopam	[256]
MR000819	Diazepam	Nordazepam	Oxidation - N-Demethylation	Diazepam	[335], [336], [337]
MR000821	Diazepam	Temazepam	Oxidation - 3-Hydroxylation	Diazepam	[338], [336], [337]
MR000825	Nordazepam	Oxazepam	Unclear - Unclear	Diazepam	[335], [336], [337]
MR000823	Temazepam	Oxazepam	Oxidation - N-Demethylation	Diazepam	[338], [337]
MR002614	Diclofenac sodium	5-hydroxy diclofenac	Oxidation - 5-Hydroxylation	Diclofenac sodium	[339], [340]
MR011193	Diphenhydramine	N-Desmethyldiphenhydramine	Unclear - Unclear	Dimenhydrinate	[11]
MR000876	Diphenhydramine	N-desmethyldiphenhydramine	Oxidation - N-Demethylation	Diphenhydramine	[341], [11], [342], [343]
MR000872	N-desmethyldiphenhydramine	N,N-didesmethyldiphenhydramine	Oxidation - N-Demethylation	Diphenhydramine	[341], [11], [342]
MR006661	Doxepin hydrochloride	N-desmethyldoxepin	Oxidation - N-demethylation	Doxepin hydrochloride	[328]
MR006686	Dronabinol	11-Hydroxy-delta-9-THC	Oxidation - 11-hydroxylation	Dronabinol	[11], [344], [345], [346]
MR006696	Dronabinol	11-OH-delata-Tetrahydrocannabinol	Oxidation - Aliphatic hydroxylation	Dronabinol	[11], [75]
MR002843	Dydrogesterone	20alpha-dihydroxydydrogesterone	Oxidation - Hydroxylation	Dydrogesterone	[150]
MR007446	E-7070	Unclear	Unclear - Unclear	E-7070	[260]
MR012208	E2101	E2101 M2	Unclear - Unclear	E2101	[280]
MR012210	E2101	E2101 M4	Unclear - Unclear	E2101	[280]
MR012211	E2101	E2101 M1	Unclear - Unclear	E2101	[280]
MR006849	Eletriptan hydrobromide	N-Desmethyl eletriptan	Oxidation - N-demethylation	Eletriptan hydrobromide	[151]
MR006851	Eliglustat tartrate	Genz-256416	Oxidation - Oxidationn	Eliglustat tartrate	[347]
MR006868	AGI-16903	Unclear	Unclear - Unclear	Enasidenib	[348]
MR006867	Enasidenib	AGI-16903	Oxidation - N-dealkylation	Enasidenib	[348]
MR006869	Encorafenib	Encorafenib dealkylation	Oxidation - N-dealkylation	Encorafenib	[175]
MR006964	EPX-100	EPX-100 M1	Oxidation - Oxidationn	EPX-100	[286]
MR000942	Escitalopram	S-desmethylcitalopram	Oxidation - N-Demethylation	Escitalopram	[324], [349]
MR000943	Escitalopram	Escitalopram propionic acid	Unclear - Unclear	Escitalopram	[350]
MR000955	Esomeprazole	5-O-Desmethylomeprazole	Oxidation - O-Dealkylation	Esomeprazole	[351]
MR000956	Esomeprazole	5-hydroxyomeprazole	Oxidation - 5-Hydroxylation	Esomeprazole	[352]
MR002696	Estrone	2-hydroxyestrone	Oxidation - Hydroxylation	Estrone	[353]
MR007159	Etizolam	alpha-hydroxyetizolam	Oxidation - 1'-hydroxylation	Etizolam	[212], [354]
MR000989	Etravirine	Etravirine metabolite M3	Oxidation - Hydroxylation	Etravirine	[98], [355]
MR000985	Etravirine metabolite M3	Etravirine metabolite M4	Oxidation - Hydroxylation	Etravirine	[355]
MR001011	Fedratinib hydrochloride	.	Unclear - Unclear	Fedratinib hydrochloride	[356], [26]
MR001018	Felbamate	2-Phenyl-1,3-propanediol monocarbamate	Hydrolysis - Esterase Hydrolysis	Felbamate	[357]
MR012196	Fenfluramine	Norfenfluramine	Unclear - Unclear	Fenfluramine	[358]
MR005476	Fexinidazole	Fexinidazole sulfoxide metabolite (M1)	Oxidation - Oxidationn	Fexinidazole	[241], [242]
MR005477	Fexinidazole sulfoxide metabolite (M1)	Fexinidazole sulfone metabolite (M2)	Oxidation - Oxidationn	Fexinidazole	[241], [242]
MR001054	Flibanserin	6-hydroxy-flibanserin-6-sulfate	Oxidation - Deamination	Flibanserin	[153], [359]
MR007193	Flunitrazepam	Desmethylflunitrazepam	Oxidation - Demethylation	Flunitrazepam	[360], [361], [362]
MR005014	4-Trifluoromethylphenol	Hippuric acid	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[363]
MR005014	4-Trifluoromethylphenol	Hippuric acid	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[363]
MR005012	Fluoxetine hydrochloride	Norfluoxetine	Oxidation - N-demethylation	Fluoxetine hydrochloride	[328], [11], [364], [365]
MR005018	Fluoxetine hydrochloride	4-Trifluoromethylphenol	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[366], [365]
MR005013	Norfluoxetine	4-Trifluoromethylphenol	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[363]
MR002944	Formoterol	O-demethylated formoterol	Oxidation - O-demethylation	Formoterol	[312], [53]
MR003172	Phenytoin	Phenytoin arene-oxide	Oxidation - Oxidation	Fosphenytoin sodium	[328]
MR007835	Propofol	4-Hydroxypropofol	Unclear - Unclear	Fospropofol disodium	[15]
MR012034	Fruquintinib	M409-1	Unclear - Unclear	fruquintinib	[367], [221]
MR011675	Ganaxolone	16-OH ganazolone	Oxidation - Hydroxylation	Ganaxolone	[368]
MR009806	GDC-0623	GDC-0623 M14	Unclear - Unclear	GDC-0623	[271]
MR009805	GDC-0623 M15	GDC-0623 M13	Unclear - Unclear	GDC-0623	[271]
MR007218	Glibenclamide	2-trans-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[369], [370]
MR007219	Glibenclamide	4-cis-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[369], [370]
MR007220	Glibenclamide	3-trans-Hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[369], [370]
MR007221	Glibenclamide	Ethylhydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[369], [370]
MR007219	Glibenclamide	4-trans-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[369], [370], [371]
MR007222	Glibenclamide	3-cis-Hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[369], [370], [371]
MR007223	Gliclazide	Methylhydroxygliclazide	Oxidation - Hydrolyzationn	Gliclazide	[11], [372]
MR007229	Gliquidone	Unclear	Unclear - Unclear	Gliquidone	[373]
MR006129	GTPL7557	Pipotiazine sulfoxyde	Oxidation - Sulfoxidation	GTPL7557	[266], [374]
MR006056	Fexinidazole Sulfone M1	Fexinidazole Sulfone M2	Oxidation - Oxidationn	HOE-239	[241]
MR006055	HOE-239	Fexinidazole Sulfone M1	Oxidation - Oxidationn	HOE-239	[241]
MR012344	HPPH	Catechol	Unclear - Unclear	HPPH	[257]
MR005118	6-alpha-hydrocodol	6-alpha-hydromorphol	Oxidation - O-demethylation	Hydrocodone bitartrate	[375]
MR005116	6-beta-hydrocodol	6-beta-hydromorphol	Oxidation - O-demethylation	Hydrocodone bitartrate	[375]
MR005109	Hydrocodone bitartrate	Hydromorphone	Oxidation - O-demethylation	Hydrocodone bitartrate	[43]
MR004644	Ibuprofen	2-Hydroxyibuprofen	Oxidation - 2-hydroxylation	Ibuprofen	[11]
MR005774	Iclaprim	Unclear	Unclear - Unclear	Iclaprim	[154]
MR012970	GS-563117	Idelalisib Metabolite M19	Unclear - Unclear	Idelalisib	[4]
MR004650	Ifosfamide	4-Hydroxyifosfamide	Oxidation - 4-hydroxylation	Ifosfamide	[331]
MR012008	Imatinib	Other imatinib metabolites	Unclear - Unclear	Imatinib	[376]
MR012989	Imipramine hydrochloride	2-hydroxyimipramine	Oxidation - 2-hydroxylation	Imipramine hydrochloride	[328]
MR012986	Imipramine hydrochloride	Desipramine	Oxidation - N-demethylation	Imipramine hydrochloride	[173]
MR003660	INCB-024360 Metabolite M11	INCB-024360 Metabolite M12	Oxidation - N-dealkylation	INCB-024360	[233]
MR001200	Indomethacin	5-hydroxyindomethacin	Oxidation - O-Demethylation	Indomethacin	[377]
MR012487	JI-101	JI-101 M1	Oxidation - Dihydroxylation	JI-101	[258]
MR013337	JNJ-54135419	Noresketamine	Oxidation - N-demethylation	JNJ-54135419	[378]
MR001328	Diazepam	Nordazepam	Unclear - Unclear	Ketazolam	[213], [336]
MR011895	KRP-297	KRP-297 Metabolite M28	Unclear - Unclear	KRP-297	[274]
MR001399	Lacosamide	O-Desmethyl-lacosamide	Oxidation - Demethylation	Lacosamide	[379]
MR012374	Ladostigil	R-MCPAI	Oxidation - Demethylation	Ladostigil	[254]
MR001414	Lansoprazole	Lansoprazole sulfone	Oxidation - Sulfoxidation	Lansoprazole	[380]
MR010933	Lenvatinib	O-demethyl Lenvatinib	Unclear - Unclear	Lenvatinib	[123]
MR003108	Lesinurad	Lesinurad metabolite M3	Oxidation - Hydroxylation	Lesinurad	[74]
MR001505	Levomilnacipran	N-desethyl LVM	Oxidation - Desmethylation	Levomilnacipran	[381]
MR012306	LIK-066	LIK-066 M13,14	Oxidation - Oxidation	LIK-066	[244]
MR005383	Linalool	8-hydroxy-linalool	Oxidation - Oxidationn	Linalool	[293], [294], [295]
MR001583	Lofexidine	N-(2-aminoethyl)-2-(2,6-dichlorophenoxy)propanamide	Oxidation - Hydroxylation	Lofexidine	[214]
MR001581	N-(2-aminoethyl)-2-(2,6-dichlorophenoxy)propanamide	2,6-dichlorophenol	Oxidation - Oxidative Deamination	Lofexidine	[214]
MR001582	N-(2-aminoethyl)-2-(2,6-dichlorophenoxy)propanamide	2-(2,6-dichlorophenoxy) propionic acid	Oxidation - Oxidative Deamination	Lofexidine	[214]
MR006893	Lomitapide mesylate	Lomitapide metabolite M1	Other reaction - Cleavage	Lomitapide mesylate	[156]
MR006894	Lomitapide mesylate	Lomitapide metabolite M3	Unclear - Unclear	Lomitapide mesylate	[156]
MR006901	Loratadine	Desloratadine	Oxidation - Oxidationn	Loratadine	[157]
MR006906	Lorcaserin	N-hydroxylorcaserin	Oxidation - Hydrolyzationn	Lorcaserin	[57]
MR006912	Lorlatinib	Lorlatinib benzoic acid metabolite (M8)	Oxidation - Oxidationn cleavage	Lorlatinib	[382]
MR006922	beta-hydroxy acid of lovastatin	6'-beta-Hydroxylovastatin	Oxidation - Hydrolyzationn	Lovastatin	[81]
MR006925	Loxapine succinate	Loxapine N-oxide	Oxidation - Oxidationn	Loxapine succinate	[101]
MR006926	Loxapine succinate	7-Hydroxyloxapine	Oxidation - Oxidationn	Loxapine succinate	[101]
MR006927	Loxapine succinate	Amoxapine	Oxidation - Oxidationn	Loxapine succinate	[101]
MR001602	Lumiracoxib	Lumiracoxib metabolite M21	Oxidation - Methyl-Hydroxylation	Lumiracoxib	[11]
MR001603	Lumiracoxib	Lumiracoxib metabolite M23	Oxidation - Hydroxylation	Lumiracoxib	[11]
MR003762	LY-450139	LY-2484595 Metabolite M3	Oxidation - Benzylic hydroxylation	LY-450139	[231]
MR001609	Lynestrenol	Norethindrone	Unclear - Unclear	Lynestrenol	[37]
MR001605	Norethindrone	Lynestrenol metabolite M1/Lynestrenol metaboliteM2	Oxidation - Hydroxylation	Lynestrenol	[37]
MR006937	Macitentan	Aprocitentan	Oxidation - Depropylation	Macitentan	[383]
MR006942	Macitentan	Macitentan metabolite M7	Oxidation - Hydrolyzationn	Macitentan	[383]
MR010182	Mavacamten	MYK-1078	Unclear - Unclear	Mavacamten	[384]
MR003317	Melatonin	6-hydroxymelatonin	Oxidation - 6-Hydroxylation	Melatonin	[11]
MR003315	Melatonin	Dihydroxy ketobemidone	Oxidation - O-Demethylation	Melatonin	[11]
MR013111	Meperidine	Normeperidine	Oxidation - N-demethylation	Meperidine	[385], [386], [44]
MR009969	Mephenytoin	4'-hydroxymephenytoin	Oxidation - Hydroxylation	Mephenytoin	[387]
MR009998	Methadone	EDDP	Oxidation - N-demethylation	Methadone	[125], [388]
MR013388	Ethylphenidate	5-Hydroxy-EPH	Unclear - Unclear	Methylphenidate	[8]
MR013389	Ethylphenidate	4-Hydroxy-EPH	Unclear - Unclear	Methylphenidate	[8]
MR013395	Metoclopramide hydrochloride	Metoclopramide hydrochloride Metabolite M4	Oxidation - Oxidationn	Metoclopramide hydrochloride	[389]
MR013401	Metoclopramide hydrochloride	Metoclopramide hydrochloride Metabolite M3	Oxidation - N-dealkylation	Metoclopramide hydrochloride	[389]
MR013406	Metoclopramide hydrochloride	Metoclopramide hydrochloride Metabolite M10	Oxidation - Nitration	Metoclopramide hydrochloride	[389]
MR004714	Metoprolol succinate	Deisopropylmetoprolol	Oxidation - N-dealkylation	Metoprolol succinate	[75]
MR004723	Metoprolol tartrate	Deisopropylmetoprolol	Oxidation - N-dealkylation	Metoprolol tartrate	[75]
MR001667	8-hydroxyminaserin	8-hydroxy-N-desmethylmianserin	Oxidation - N-Dealkylation	Mianserin	[202]
MR004749	Desglymidodrine	Midodrine Metabolite M-2	Oxidation - 5'-O-demethylation	Midodrine	[126]
MR001685	Milnacipran	N-Desethyl milnacipran	Oxidation - Desethylation	Milnacipran	[215]
MR007630	ML-3000	Licofelone M4	Oxidation - Hydrolyzationn	ML-3000	[11]
MR004802	Montelukast sodium	25-OH Montelukast	Unclear - Unclear	Montelukast sodium	[16]
MR003382	R-Naftopidil	R-Naftopidil metabolite M1	Unclear - Unclear	Naftopidil	[195], [390]
MR003384	R-Naftopidil	R-Naftopidil metabolite M3	Unclear - Unclear	Naftopidil	[195], [390]
MR003385	S-Naftopidil	R-Naftopidil metabolite M1	Unclear - Unclear	Naftopidil	[195], [390]
MR008825	Nalbuphine	3'-hydroxynalbuphine	Oxidation - Hydroxylation	Nalbuphine	[102]
MR008826	Nalbuphine	4'-hydroxynalbuphine	Oxidation - Hydroxylation	Nalbuphine	[102]
MR013408	Nebivolol hydrochloride	4-hydroxy Nebivolol	Oxidation - 4-hydroxylation	Nebivolol hydrochloride	[180]
MR001719	Nelfinavir mesylate	Nelfinavir hydroxyl-t- butylamide	Oxidation - Hydroxylation	Nelfinavir mesylate	[391], [392]
MR009257	N-despropyl-rotigotine	Neupro Metabolite M2	Unclear - Unclear	Neupro	[393], [196]
MR009255	Neupro	N-despropyl-rotigotine	Unclear - Unclear	Neupro	[393], [196]
MR003319	4-hydroxynimesulideM1	Nimesulide metabolite M2	Unclear - Unclear	Nimesulide	[394]
MR007640	Nomifensine	Nomifensine H1	Unclear - Unclear	Nomifensine	[281]
MR007638	Nomifensine	Nomifensine H4	Unclear - Unclear	Nomifensine	[281]
MR007636	Nomifensine	Nomifensinc N-hydroxylamine (H6)	Unclear - Unclear	Nomifensine	[281]
MR001783	Norethindrone acetate	Norethindrone acetate metabolite M1,M2	Oxidation - Hydroxylation	Norethindrone acetate	[37]
MR001796	Nortriptyline hydrochloride	Desmethylnortriptyline	Unclear - Unclear	Nortriptyline hydrochloride	[395], [396]
MR001830	Omeprazole	5-hydroxyomeprazole	Oxidation - 5-Hydroxylation	Omeprazole	[11]
MR001831	Omeprazole	5'-O-Desmethyl omeprazole	Oxidation - 5'-O-Demethylation	Omeprazole	[11]
MR001857	Ospemifene	4-hydroxylation Ospemifene	Unclear - Unclear	Ospemifene	[103]
MR003156	Oxymetazoline	Oxymetazoline metabolite M2	Oxidation - Oxidative Dehydrogenation	Oxymetazoline	[187]
MR003152	Oxymetazoline metabolite M2	Oxymetazoline metabolite M3	Oxidation - Monohydroxylation	Oxymetazoline	[187]
MR003155	Oxymetazoline metabolite M8	Oxymetazoline metabolite M1	Oxidation - Hydroxylation	Oxymetazoline	[187]
MR001938	Pantoprazole Sodium	Desmethylpantoprazole	Oxidation - Demethylation	Pantoprazole Sodium	[128]
MR003337	Paroxetine hydrochloride	Paroxetine catechol	Unclear - Unclear	Paroxetine hydrochloride	[11], [104]
MR001972	Pentamidine isethionate	Pentamidine Amidoxime	Oxidation - N-Hydroxylation	Pentamidine isethionate	[182], [159]
MR001974	Pentobarbital	4-hydroxyphenobarbital	Oxidation - Hydroxylation	Pentobarbital	[105]
MR001985	N-desmethylperazine	N-{3-(phenothiazinyl-10)-propyl}ethylenediamine	Oxidation - N-Dealkylation	Perazine	[397]
MR002005	Perphenazine	N-Dealkylated perphenazine	Oxidation - N-Dealkylation	Perphenazine	[398]
MR010398	PF-04937319	PF-04937319 Metabolite M1	Oxidation - N-demethylation	PF-04937319	[261]
MR005388	PF-04965842	Abrocitinib M4 metabolite	Oxidation - Oxidationn	PF-04965842	[399]
MR005393	PF-04965842	Abrocitinib M1 metabolite	Oxidation - Oxidationn	PF-04965842	[399]
MR005400	PF-04965842	Abrocitinib M3 metabolite	Oxidation - Oxidationn	PF-04965842	[399]
MR005397	PF-04965842	Abrocitinib M2 metabolite	Oxidation - Oxidationn	PF-04965842	[399]
MR012168	PF-04965842	PF-04965842 Metabolites M1	Unclear - Unclear	PF-04965842	[400]
MR012178	PF-04965842	PF-04965842 Metabolites M2	Unclear - Unclear	PF-04965842	[401]
MR011750	PF-06463922	PF-06895751 (M8)	Unclear - Unclear	PF-06463922	[243]
MR006396	Hydroxytriptolide	Trihydroxytriptolide	Unclear - Unclear	PG-490	[224]
MR006395	PG-490	Hydroxytriptolide	Oxidation - Hydrolyzationn	PG-490	[224]
MR006401	PG-490	Dihydroxytriptolide	Oxidation - Hydrolyzationn	PG-490	[224]
MR006406	PG-490	Hydrolyzed hydroxytriptolide	Oxidation - Hydrolyzationn	PG-490	[224]
MR006408	PG-490	Hydrolyzed triptolide	Oxidation - Hydrolyzationn	PG-490	[224]
MR002018	Phenelzine	Phenethylamine	Hydrolysis - Hydrolysis	Phenelzine	[402]
MR002023	Phenobarbital	4-hydroxyphenobarbital	Oxidation - 4-Hydroxylation	Phenobarbital	[11]
MR002024	Phenobarbital	Mephobarbital	Conjugation - Methylation	Phenobarbital	[403]
MR002030	Hydroxyphenytoin	Phenytoin catechol	Oxidation - Oxidation	Phenytoin	[328]
MR002036	Phenytoin	Phenytoin dihydrodiol	Oxidation - Dihydroxylation; Oxidation	Phenytoin	[11]
MR002035	Phenytoin	Phenytoin arene-oxide	Oxidation - Oxidation	Phenytoin	[328]
MR002088	R-95913	R-138727	Unclear - Unclear	Prasugrel hydrochloride	[11], [404], [405], [406]
MR002111	Nordazepam	Oxazepam	Oxidation - Hydroxylation	Prazepam	[407], [408], [409]
MR002112	Praziquantel	10-hydroxypraziquantel	Oxidation - Hydroxylation	Praziquantel	[410], [411], [182]
MR002149	Primidone	Phenylethylmalonamide (PEMA)	Unclear - Unclear	Primidone	[412], [413]
MR002150	Primidone	Phenobarbital	Unclear - Unclear	Primidone	[412], [413], [414], [415]
MR002166	Prochlorperazine	N-demethylation	Oxidation - N-Demethylation	Prochlorperazine	[107], [416], [417]
MR002167	Prochlorperazine	Prochlorperazine sulfoxide	Oxidation - Sulfoxidation	Prochlorperazine	[107], [416], [417]
MR002168	Prochlorperazine	Prochlorperazine 7-hydroxide	Oxidation - 7-Hydroxylation	Prochlorperazine	[107], [416], [417]
MR002172	Progesterone	Desoxycortone	Oxidation - Hydroxylation	Progesterone	[17]
MR002170	Progesterone	16alpha-hydroxyprogesterone	Oxidation - Hydroxylation	Progesterone	[17]
MR005189	Proguanil	Cycloguanil	Other reaction - Cyclisation	Proguanil	[418], [419], [420]
MR005190	Proguanil	4-Chlorophenylbiguanide	Oxidation - N-dealkylation	Proguanil	[419], [420]
MR002782	Promazine	N-Desmethylpromazine	Oxidation - N-Demethylation	Promazine	[79]
MR013642	PT2385	PT2385 M7	Oxidation - Oxidative Defluorination	PT2385	[246]
MR013643	PT2385 M7	PT2385 M12	Multi-steps Reaction - Oxidative Defluorination; Glucuronide conjugation	PT2385	[246]
MR005431	PT2977	Unclear	Unclear - Unclear	PT2977	[421]
MR012497	PTC299	O-Desmethyl emvododstat	Unclear - Unclear	PTC299	[262]
MR002788	Quazepam	2-Oxoquazepam	Hydrolysis - Hydrolysis	Quazepam	[162]
MR010018	Quinine sulfate	Quinine sulfate Metabolite M3	Oxidation - Demethylation	Quinine sulfate	[422]
MR010016	Quinine sulfate	Quinine sulfate Metabolite M1	Oxidation - Hydroxylation	Quinine sulfate	[422]
MR010027	Rabeprazole sodium	Desmethylrabeprazole	Unclear - Unclear	Rabeprazole sodium	[423]
MR013046	Ranitidine	Desmethylranitidine	Oxidation - N-demethylation	Ranitidine	[131]
MR008491	Remogliflozin	GSK279782	Unclear - Unclear	Remogliflozin etabonate	[247]
MR006427	RO-111163	Moclobemide M1	Oxidation - C-oxidation	RO-111163	[424]
MR006433	RO-111163	Moclobemide M5	Oxidation - N-oxidation	RO-111163	[424]
MR006435	RO-111163	Moclobemide M3	Oxidation - Aromatic hydroxylation	RO-111163	[424]
MR006436	RO-111163	Moclobemide M9	Oxidation - Oxidationn deamination	RO-111163	[424]
MR006596	Romidepsin	Romidepsin metabolite M1	Reduction - Reduction	Romidepsin	[184]
MR009592	Rosuvastatin	N-Desmethylrosuvastatin	Oxidation - N-demethylation	Rosuvastatin	[11], [425]
MR010681	Safinamide	Safinamide Metabolite M1	Unclear - Unclear	Safinamide	[426]
MR010185	Savolitinib	Savolitinib Metabolite M2	Unclear - Unclear	Savolitinib	[427]
MR002244	Desmethylsertraline	Alpha-hydroxy sertraline ketone	Oxidation - N-Hydroxylation	Sertraline hydrochloride	[428]
MR002247	Sertraline hydrochloride	Desmethylsertraline	Oxidation - N-Demethylation	Sertraline hydrochloride	[429], [430], [431], [432]
MR002252	Sildenafil citrate	Desmethylsildenafil	Oxidation - N-Demethylation	Sildenafil citrate	[433], [434], [435]
MR002253	Sildenafil citrate	N-dealkyl Sildenafil	Oxidation - N-Dealkylation	Sildenafil citrate	[11]
MR013434	Simvastatin	6'-beta-Hydroxysimvastatin	Oxidation - Aliphatic hydroxylation	Simvastatin	[75]
MR013893	Sinomenine	N-demethyl-sinomenine	Unclear - Unclear	Sinomenine	[278]
MR004040	SQ-109	SQ-109 Metabolite M1	Oxidation - N-Nitrosylation	SQ-109	[245]
MR004044	SQ-109	SQ-109 Metabolite M4-2	Multi-steps Reaction - Ring oxidation; Epoxidation; rearrangement	SQ-109	[245]
MR004045	SQ-109	SQ-109 Metabolite M4-1	Oxidation - Ring oxidation; N-hydroxylation	SQ-109	[245]
MR004038	SQ-109	M/Z 347	Oxidation - Epoxidation	SQ-109	[245]
MR004041	SQ-109	SQ-109 Metabolite M3	Oxidation - N-Nitrosylation	SQ-109	[245]
MR004042	SQ-109	SQ-109 Metabolite M4	Oxidation - N-Dealkylation	SQ-109	[245]
MR004043	SQ-109	SQ-109 Metabolite M2-1	Oxidation - Ring oxidation	SQ-109	[245]
MR004046	SSR-97193	Mono-N-demethyl ferroquine	Unclear - Unclear	SSR-97193	[249]
MR006841	Stiripentol	Stiripentol metabolite II	Multi-steps Reaction - Oxidationn cleavage; demethylenation	Stiripentol	[436]
MR006846	Sulfadiazine	Sulfadiazine hydroxylamine	Multi-steps Reaction - Hydrolyzationn; sulfadiazine acetylation	Sulfadiazine	[132]
MR010640	Sumatriptan	N-Desmethyl sumatriptan	Unclear - Unclear	Sumatriptan	[111]
MR002313	Suvorexant	hydroxyl-suvorexant	Oxidation - Hydoxylation	Suvorexant	[437], [438], [439]
MR003510	Tamoxifen citrate	N-Desmethyltamoxifen	Oxidation - N-Dealkylation	Tamoxifen citrate	[440], [441], [442], [443], [444]
MR003526	Tamoxifen citrate	4-hydroxytamoxifen	Oxidation - 4-Hydroxylation	Tamoxifen citrate	[440], [441], [442], [445]
MR002334	Tapentadol	N-desmethyl tapentadol	Unclear - Unclear	Tapentadol	[446], [447]
MR002340	Tasimelteon	Tasimelteon metabolite M13	Oxidation - Hydroxylation	Tasimelteon	[448]
MR002338	Tasimelteon metabolite M13	Tasimelteon metabolite M9	Unclear - Unclear	Tasimelteon	[448]
MR002339	Tasimelteon metabolite M13	Tasimelteon metabolite M11	Unclear - Unclear	Tasimelteon	[448]
MR002376	O-conjugate of temazepam	Temazepam metabolite M1	Oxidation - Demethylation	Temazepam	[449], [450]
MR002378	Temazepam	Oxazepam	Oxidation - Demethylation	Temazepam	[167], [449]
MR002398	Teniposide	.	Unclear - Unclear	Teniposide	[451]
MR002399	Hydroxyterbinafine	N-Desmethylhydroxyterbinafine	Oxidation - N-Demethylation	Terbinafine hydrochloride	[29], [452]
MR002400	Hydroxyterbinafine	Carboxyterbinafine	Oxidation - Oxidation	Terbinafine hydrochloride	[29]
MR002401	N-Desmethylterbinafine	N-Desmethylhydroxyterbinafine	Oxidation - Hydoxylation	Terbinafine hydrochloride	[29]
MR002406	Terbinafine dihydrodiol derivative (1)	N-Desmethylterbinafine dihydrodiol derivative (1)	Oxidation - N-Demethylation	Terbinafine hydrochloride	[29]
MR002407	Terbinafine dihydrodiol derivative (2)	N-Desmethylterbinafine dihydrodiol derivative (2)	Oxidation - N-Demethylation	Terbinafine hydrochloride	[29]
MR002409	Terbinafine hydrochloride	N-Desmethylterbinafine	Oxidation - N-Demethylation	Terbinafine hydrochloride	[29]
MR002410	Terbinafine hydrochloride	1-Naphthaldehyde	Oxidation - Deamination	Terbinafine hydrochloride	[29]
MR002408	Terbinafine hydrochloride	Hydroxyterbinafine	Oxidation - Hydoxylation	Terbinafine hydrochloride	[29]
MR004939	Thalidomide	Thalidomide arene oxide	Oxidation - Epoxidation	Thalidomide	[11], [453]
MR004934	Thalidomide	5-Hydroxythalidomide	Oxidation - Aromatic hydroxylation	Thalidomide	[11], [453]
MR004937	Thalidomide	Cis, trans-5'-Hydroxythalidomide	Oxidation - Hydrolyzationn	Thalidomide	[11], [453]
MR004986	Thienodihydropyridinium	Thienopyridinium	Unclear - Unclear	Ticlopidine	[11]
MR004987	Ticlopidine	Ticlopidine S-oxide	Unclear - Unclear	Ticlopidine	[11]
MR004984	Ticlopidine	Thienodihydropyridinium	Oxidation - Dehydrogenation	Ticlopidine	[11]
MR004982	Ticlopidine	2-Oxoticlopidine	Unclear - Unclear	Ticlopidine	[11]
MR004992	Ticlopidine	Di-Hydroxyticlopidine	Unclear - Unclear	Ticlopidine	[11]
MR006192	Tienilic acid	Thiophene-4,5-epoxide	Oxidation - Epoxidation	Tienilic acid	[11]
MR014207	Tilidine	Nortilidine	Oxidation - N-Dealkylation	Tilidine	[454]
MR004995	M1 metabolite, timolol	Timolol maleate Metabolite M4	Unclear - Unclear	Timolol maleate	[455]
MR004996	M1 metabolite, timolol	Timolol maleate Metabolite M3	Unclear - Unclear	Timolol maleate	[455]
MR004997	Timolol maleate	Timolol maleate Metabolite M2	Unclear - Unclear	Timolol maleate	[455]
MR004994	Timolol maleate	M1 metabolite, timolol	Oxidation - Hydrolyzationn	Timolol maleate	[455], [135]
MR005003	Tipranavir	Tipranavir Metabolite	Oxidation - Monohydroxylation	Tipranavir	[456]
MR011610	Tivantinib	Tivantinib Metabolite M10	Oxidation - Oxidation	Tivantinib	[227]
MR006775	Tolbutamide	4-Hydroxy tolbutamide	Oxidation - Hydrolyzationn	Tolbutamide	[11]
MR006780	Tolterodine tartrate	N-Dealkylated tolterodine	Oxidation - N-dealkylation	Tolterodine tartrate	[11]
MR002909	TCBZ-SX	Triclabendazole sulfone metabolite	Oxidation - Oxidation	Triclabendazole	[457], [458]
MR006150	TRV-130	Oxy-oliceridine	Oxidation - Oxidationn	TRV-130	[265]
MR006152	TRV-130	TRV0109662	Oxidation - N-dealkylation	TRV-130	[265]
MR006991	VA-10872	3'-Hydroxyhexobarbital	Oxidation - 3'-hydroxylation	VA-10872	[11]
MR005638	Desvenlafaxine	N,O-Didesmethylvenlafaxine	Oxidation - N-demethylation	Venlafaxine hydrochloride	[115], [459], [460]
MR005643	N-Desmethylvenlafaxine	N,O-Didesmethylvenlafaxine	Oxidation - O-demethylation	Venlafaxine hydrochloride	[115], [459], [460]
MR005642	Venlafaxine hydrochloride	N-Desmethylvenlafaxine	Oxidation - N-demethylation	Venlafaxine hydrochloride	[115], [459], [460]
MR005637	Venlafaxine hydrochloride	Desvenlafaxine	Oxidation - O-demethylation	Venlafaxine hydrochloride	[115], [459], [460]
MR010458	Verubulin	MPI-0440627	Oxidation - O-demethylation	Verubulin	[259]
MR013238	Vilazodone hydrochloride	Vilazodone metabolite M10	Oxidation - Oxidation deamination	Vilazodone hydrochloride	[116], [461], [462]
MR013079	Vonoprazan	N-demethylated TAK-438	Oxidation - N-demethylation	Vonoprazan	[463], [200]
MR013073	Vonoprazan	Vonoprazan M-	Unclear - Unclear	Vonoprazan	[464], [200]
MR013245	Voriconazole	Voriconazole N-Oxide Metabolite	Oxidation - Oxidationn	Voriconazole	[465], [466]
MR005675	Voxelotor	Unclear	Oxidation - Oxidationn	Voxelotor	[467]
MR013261	Warfarin sodium	R-4'-Hydroxywarfarin	Oxidation - 4'-hydroxylation	Warfarin sodium	[468], [79]
MR013263	Warfarin sodium	R-6-Hydroxywarfarin	Oxidation - 6-hydroxylation	Warfarin sodium	[468], [79]
MR013267	Warfarin sodium	R-8-Hydroxywarfarin	Oxidation - 8-hydroxylation	Warfarin sodium	[468], [79]
MR013266	Warfarin sodium	S-4'-Hydroxywarfarin	Oxidation - 4'-hydroxylation	Warfarin sodium	[468], [79]
MR006493	WY-1485	NLA-715	Oxidation - Hydrolyzationn	WY-1485	[469], [50]
MR005676	Zidovudine	3'-Aminothymidine	Reduction - Reduction	Zidovudine	[50], [470]
MR005696	Zolpidem tartrate	Methoxyzolpidem derivative (M3)	Oxidation - Methyl-hydroxylation	Zolpidem tartrate	[11], [471]
MR005702	Zolpidem tartrate	Methoxyzolpidem	Oxidation - Aliphatic hydroxylation	Zolpidem tartrate	[11], [471]
MR013081	Zotepine	Norzotepine	Oxidation - N-demethylation	Zotepine	[202], [472]
MR013084	Zotepine	3-OH-zotepine	Oxidation - Aromatic hydroxylation	Zotepine	[202]
MR013085	Zotepine	Zotepine S-oxide	Oxidation - S-oxidation	Zotepine	[202]


⏷ Show the Full List of 385 MR(s)

Tissue/Disease-Specific Protein Abundances of This DME
Tissue-specific Protein Abundances in Healthy Individuals		Click to Show/Hide

Download the Tissue-Specific Variation(s) Profile
ICD Disease Classification 01	Infectious/parasitic disease	Click to Show/Hide
ICD-11: 1C1H	Necrotising ulcerative gingivitis	Click to Show/Hide
The Studied Tissue	Gingival tissue
The Specified Disease	Bacterial infection of gingival [ICD-11:1C1H]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.16E-07; Fold-change: -2.81E-01; Z-score: -7.41E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1E30	Influenza	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Influenza [ICD-11:1E30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.61E-01; Fold-change: 9.45E-02; Z-score: 4.82E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1E51	Chronic viral hepatitis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Chronic hepatitis C [ICD-11:1E51.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.35E-01; Fold-change: 3.90E-02; Z-score: 2.84E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1G41	Sepsis with septic shock	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Sepsis with septic shock [ICD-11:1G41]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.26E-03; Fold-change: 7.59E-02; Z-score: 3.47E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA40	Respiratory syncytial virus infection	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Pediatric respiratory syncytial virus infection [ICD-11:CA40.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.37E-01; Fold-change: -3.22E-02; Z-score: -3.78E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA42	Rhinovirus infection	Click to Show/Hide
The Studied Tissue	Nasal epithelium tissue
The Specified Disease	Rhinovirus infection [ICD-11:CA42.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.48E-01; Fold-change: 1.51E-02; Z-score: 1.06E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: KA60	Neonatal sepsis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Neonatal sepsis [ICD-11:KA60]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.08E-01; Fold-change: 2.70E-03; Z-score: 1.32E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 02	Neoplasm	Click to Show/Hide
ICD-11: 2A00	Brain cancer	Click to Show/Hide
The Studied Tissue	Nervous tissue
The Specified Disease	Glioblastopma [ICD-11:2A00.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.91E-02; Fold-change: -6.39E-02; Z-score: -2.08E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Brain stem tissue
The Specified Disease	Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.14E-01; Fold-change: -2.20E-02; Z-score: -3.18E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	White matter tissue
The Specified Disease	Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.16E-04; Fold-change: -6.72E-01; Z-score: -1.83E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Brain stem tissue
The Specified Disease	Neuroectodermal tumour [ICD-11:2A00.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.94E-05; Fold-change: -9.30E-01; Z-score: -2.34E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A20	Myeloproliferative neoplasm	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Myelofibrosis [ICD-11:2A20.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.74E-01; Fold-change: -1.64E-01; Z-score: -9.73E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Whole blood
The Specified Disease	Polycythemia vera [ICD-11:2A20.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.88E-02; Fold-change: 2.48E-02; Z-score: 1.36E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A36	Myelodysplastic syndrome	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Myelodysplastic syndrome [ICD-11:2A36-2A3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.92E-01; Fold-change: -9.92E-03; Z-score: -4.27E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 5.09E-01; Fold-change: 1.86E-02; Z-score: 2.09E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2A81	Diffuse large B-cell lymphoma	Click to Show/Hide
The Studied Tissue	Tonsil tissue
The Specified Disease	Diffuse large B-cell lymphoma [ICD-11:2A81]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.46E-01; Fold-change: 8.52E-02; Z-score: 5.47E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A83	Plasma cell neoplasm	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.82E-03; Fold-change: 1.37E-01; Z-score: 1.05E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Bone marrow
The Specified Disease	Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.09E-05; Fold-change: -6.05E-01; Z-score: -3.19E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2B33	Leukaemia	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Acute myelocytic leukaemia [ICD-11:2B33.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.34E-01; Fold-change: 4.42E-03; Z-score: 2.22E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2B6E	Oral cancer	Click to Show/Hide
The Studied Tissue	Oral tissue
The Specified Disease	Oral cancer [ICD-11:2B6E]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.40E-03; Fold-change: -4.39E-01; Z-score: -9.19E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 4.74E-11; Fold-change: -4.64E-01; Z-score: -9.83E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B70	Esophageal cancer	Click to Show/Hide
The Studied Tissue	Esophagus
The Specified Disease	Esophagal cancer [ICD-11:2B70]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 4.88E-01; Fold-change: -5.48E-02; Z-score: -1.19E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: 2B72	Stomach cancer	Click to Show/Hide
The Studied Tissue	Gastric tissue
The Specified Disease	Gastric cancer [ICD-11:2B72]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.38E-01; Fold-change: -5.76E-01; Z-score: -8.98E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.02E-03; Fold-change: -6.68E-01; Z-score: -1.13E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B90	Colon cancer	Click to Show/Hide
The Studied Tissue	Colon tissue
The Specified Disease	Colon cancer [ICD-11:2B90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.98E-01; Fold-change: -6.06E-02; Z-score: -1.56E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 6.24E-02; Fold-change: -5.65E-02; Z-score: -1.91E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B92	Rectal cancer	Click to Show/Hide
The Studied Tissue	Rectal colon tissue
The Specified Disease	Rectal cancer [ICD-11:2B92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.51E-02; Fold-change: 1.95E-01; Z-score: 1.20E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 5.25E-01; Fold-change: -2.30E-02; Z-score: -2.21E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C10	Pancreatic cancer	Click to Show/Hide
The Studied Tissue	Pancreas
The Specified Disease	Pancreatic cancer [ICD-11:2C10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.82E-02; Fold-change: -4.38E-02; Z-score: -1.55E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.22E-01; Fold-change: -1.19E-01; Z-score: -1.12E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C12	Liver cancer	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Liver cancer [ICD-11:2C12.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.41E-18; Fold-change: -4.32E+00; Z-score: -2.45E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 8.73E-75; Fold-change: -2.45E+00; Z-score: -2.20E+00
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 4.98E-03; Fold-change: -4.54E+00; Z-score: -4.27E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual Download DME expression data in the tissue of the other disease section
ICD-11: 2C25	Lung cancer	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Lung cancer [ICD-11:2C25]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.08E-02; Fold-change: 2.60E-02; Z-score: 1.59E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.07E-01; Fold-change: 1.26E-02; Z-score: 6.37E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C30	Skin cancer	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Melanoma [ICD-11:2C30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.42E-01; Fold-change: -1.13E-02; Z-score: -1.81E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Skin
The Specified Disease	Skin cancer [ICD-11:2C30-2C3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.87E-01; Fold-change: -1.26E-02; Z-score: -3.57E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.08E-12; Fold-change: 3.02E-01; Z-score: 7.54E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C6Z	Breast cancer	Click to Show/Hide
The Studied Tissue	Breast tissue
The Specified Disease	Breast cancer [ICD-11:2C60-2C6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.84E-13; Fold-change: -1.34E-01; Z-score: -3.71E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.53E-03; Fold-change: -1.35E-01; Z-score: -5.64E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C73	Ovarian cancer	Click to Show/Hide
The Studied Tissue	Ovarian tissue
The Specified Disease	Ovarian cancer [ICD-11:2C73]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.74E-01; Fold-change: -3.97E-02; Z-score: -1.15E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 7.54E-01; Fold-change: -1.36E-01; Z-score: -6.78E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C77	Cervical cancer	Click to Show/Hide
The Studied Tissue	Cervical tissue
The Specified Disease	Cervical cancer [ICD-11:2C77]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.73E-03; Fold-change: -7.15E-01; Z-score: -1.21E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C78	Uterine cancer	Click to Show/Hide
The Studied Tissue	Endometrium tissue
The Specified Disease	Uterine cancer [ICD-11:2C78]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.07E-03; Fold-change: -2.00E-01; Z-score: -3.54E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.35E-04; Fold-change: 3.68E-01; Z-score: 2.95E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C82	Prostate cancer	Click to Show/Hide
The Studied Tissue	Prostate
The Specified Disease	Prostate cancer [ICD-11:2C82]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.39E-02; Fold-change: -2.78E-01; Z-score: -5.67E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C90	Renal cancer	Click to Show/Hide
The Studied Tissue	Kidney
The Specified Disease	Renal cancer [ICD-11:2C90-2C91]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.02E-01; Fold-change: -2.84E-01; Z-score: -7.34E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.37E-10; Fold-change: -3.97E-01; Z-score: -1.14E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C92	Ureter cancer	Click to Show/Hide
The Studied Tissue	Urothelium
The Specified Disease	Ureter cancer [ICD-11:2C92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.13E-01; Fold-change: -1.54E-01; Z-score: -8.59E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C94	Bladder cancer	Click to Show/Hide
The Studied Tissue	Bladder tissue
The Specified Disease	Bladder cancer [ICD-11:2C94]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.77E-05; Fold-change: 6.14E-01; Z-score: 3.59E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D02	Retinal cancer	Click to Show/Hide
The Studied Tissue	Uvea
The Specified Disease	Retinoblastoma [ICD-11:2D02.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.72E-03; Fold-change: -2.24E-01; Z-score: -1.31E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D10	Thyroid cancer	Click to Show/Hide
The Studied Tissue	Thyroid
The Specified Disease	Thyroid cancer [ICD-11:2D10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.10E-03; Fold-change: 5.38E-02; Z-score: 2.83E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 6.07E-01; Fold-change: -2.32E-02; Z-score: -1.41E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2D11	Adrenal cancer	Click to Show/Hide
The Studied Tissue	Adrenal cortex
The Specified Disease	Adrenocortical carcinoma [ICD-11:2D11.Z]
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 1.91E-01; Fold-change: -8.69E-02; Z-score: -6.82E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
ICD-11: 2D12	Endocrine gland neoplasm	Click to Show/Hide
The Studied Tissue	Pituitary tissue
The Specified Disease	Pituitary cancer [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.64E-01; Fold-change: -4.67E-03; Z-score: -1.80E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Pituitary tissue
The Specified Disease	Pituitary gonadotrope tumour [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.12E-01; Fold-change: 6.83E-03; Z-score: 2.98E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D42	Head and neck cancer	Click to Show/Hide
The Studied Tissue	Head and neck tissue
The Specified Disease	Head and neck cancer [ICD-11:2D42]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.49E-08; Fold-change: -1.53E-01; Z-score: -6.35E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 03	Blood/blood-forming organ disease	Click to Show/Hide
ICD-11: 3A51	Sickle cell disorder	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Sickle cell disease [ICD-11:3A51.0-3A51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.89E-01; Fold-change: 6.53E-02; Z-score: 3.44E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3A70	Aplastic anaemia	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Shwachman-Diamond syndrome [ICD-11:3A70.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.67E-02; Fold-change: 8.33E-01; Z-score: 1.75E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3B63	Thrombocytosis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Thrombocythemia [ICD-11:3B63]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.62E-01; Fold-change: 1.75E-02; Z-score: 1.07E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3B64	Thrombocytopenia	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Thrombocytopenia [ICD-11:3B64]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.71E-01; Fold-change: -2.25E-04; Z-score: -8.56E-04
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 04	Immune system disease	Click to Show/Hide
ICD-11: 4A00	Immunodeficiency	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Immunodeficiency [ICD-11:4A00-4A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.70E-01; Fold-change: -1.38E-02; Z-score: -1.75E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A40	Lupus erythematosus	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Lupus erythematosus [ICD-11:4A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.94E-01; Fold-change: -6.72E-02; Z-score: -1.65E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A42	Systemic sclerosis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Scleroderma [ICD-11:4A42.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.73E-01; Fold-change: -6.49E-02; Z-score: -5.42E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A43	Systemic autoimmune disease	Click to Show/Hide
The Studied Tissue	Salivary gland tissue
The Specified Disease	Sjogren's syndrome [ICD-11:4A43.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.05E-02; Fold-change: 2.38E-01; Z-score: 2.17E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 9.91E-02; Fold-change: -1.61E-01; Z-score: -1.20E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 4A62	Behcet disease	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Behcet's disease [ICD-11:4A62]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.03E-01; Fold-change: 1.00E-01; Z-score: 6.91E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4B04	Monocyte count disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Autosomal dominant monocytopenia [ICD-11:4B04]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.72E-02; Fold-change: 3.38E-02; Z-score: 2.42E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 05	Endocrine/nutritional/metabolic disease	Click to Show/Hide
ICD-11: 5A11	Type 2 diabetes mellitus	Click to Show/Hide
The Studied Tissue	Omental adipose tissue
The Specified Disease	Obesity related type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.55E-02; Fold-change: 1.59E-01; Z-score: 1.72E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Liver tissue
The Specified Disease	Type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.80E-01; Fold-change: 1.81E-02; Z-score: 3.07E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5A80	Ovarian dysfunction	Click to Show/Hide
The Studied Tissue	Vastus lateralis muscle
The Specified Disease	Polycystic ovary syndrome [ICD-11:5A80.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.62E-02; Fold-change: -6.86E-02; Z-score: -6.03E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C51	Inborn carbohydrate metabolism disorder	Click to Show/Hide
The Studied Tissue	Biceps muscle
The Specified Disease	Pompe disease [ICD-11:5C51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.43E-02; Fold-change: -1.55E-01; Z-score: -6.44E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C56	Lysosomal disease	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Batten disease [ICD-11:5C56.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.80E-01; Fold-change: -3.14E-02; Z-score: -1.69E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C80	Hyperlipoproteinaemia	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.87E-01; Fold-change: 2.95E-02; Z-score: 2.13E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Whole blood
The Specified Disease	Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.03E-02; Fold-change: -1.19E-01; Z-score: -5.11E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 06	Mental/behavioural/neurodevelopmental disorder	Click to Show/Hide
ICD-11: 6A02	Autism spectrum disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Autism [ICD-11:6A02]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.63E-01; Fold-change: -6.81E-02; Z-score: -4.02E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A20	Schizophrenia	Click to Show/Hide
The Studied Tissue	Prefrontal cortex
The Specified Disease	Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.39E-01; Fold-change: 1.54E-02; Z-score: 4.74E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Superior temporal cortex
The Specified Disease	Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.64E-02; Fold-change: -8.21E-02; Z-score: -7.11E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A60	Bipolar disorder	Click to Show/Hide
The Studied Tissue	Prefrontal cortex
The Specified Disease	Bipolar disorder [ICD-11:6A60-6A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.11E-01; Fold-change: -4.04E-02; Z-score: -2.22E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A70	Depressive disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.66E-01; Fold-change: -1.33E-02; Z-score: -3.98E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Hippocampus
The Specified Disease	Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.66E-01; Fold-change: 9.19E-03; Z-score: 4.88E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 08	Nervous system disease	Click to Show/Hide
ICD-11: 8A00	Parkinsonism	Click to Show/Hide
The Studied Tissue	Substantia nigra tissue
The Specified Disease	Parkinson's disease [ICD-11:8A00.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.62E-01; Fold-change: 2.57E-02; Z-score: 1.10E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A01	Choreiform disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Huntington's disease [ICD-11:8A01.10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.35E-01; Fold-change: 1.08E-01; Z-score: 6.56E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A20	Alzheimer disease	Click to Show/Hide
The Studied Tissue	Entorhinal cortex
The Specified Disease	Alzheimer's disease [ICD-11:8A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.40E-01; Fold-change: -3.31E-02; Z-score: -1.97E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A2Y	Neurocognitive impairment	Click to Show/Hide
The Studied Tissue	White matter tissue
The Specified Disease	HIV-associated neurocognitive impairment [ICD-11:8A2Y-8A2Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.72E-01; Fold-change: -4.99E-03; Z-score: -3.09E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A40	Multiple sclerosis	Click to Show/Hide
The Studied Tissue	Plasmacytoid dendritic cells
The Specified Disease	Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.44E-01; Fold-change: -1.85E-01; Z-score: -5.25E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Spinal cord
The Specified Disease	Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 7.48E-01; Fold-change: -6.47E-02; Z-score: -7.38E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: 8A60	Epilepsy	Click to Show/Hide
The Studied Tissue	Peritumoral cortex tissue
The Specified Disease	Epilepsy [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 7.52E-01; Fold-change: 6.78E-02; Z-score: 2.41E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
The Studied Tissue	Whole blood
The Specified Disease	Seizure [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.70E-01; Fold-change: -2.22E-02; Z-score: -1.17E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B01	Subarachnoid haemorrhage	Click to Show/Hide
The Studied Tissue	Intracranial artery
The Specified Disease	Intracranial aneurysm [ICD-11:8B01.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.97E-01; Fold-change: -1.01E-01; Z-score: -4.23E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B11	Cerebral ischaemic stroke	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Cardioembolic stroke [ICD-11:8B11.20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.79E-01; Fold-change: 6.76E-02; Z-score: 3.66E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Peripheral blood
The Specified Disease	Ischemic stroke [ICD-11:8B11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.72E-01; Fold-change: 2.64E-02; Z-score: 2.26E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B60	Motor neuron disease	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.32E-02; Fold-change: 1.30E-01; Z-score: 7.89E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Cervical spinal cord
The Specified Disease	Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.49E-01; Fold-change: 5.15E-02; Z-score: 1.92E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8C70	Muscular dystrophy	Click to Show/Hide
The Studied Tissue	Muscle tissue
The Specified Disease	Myopathy [ICD-11:8C70.6]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.28E-02; Fold-change: -1.96E-01; Z-score: -1.04E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8C75	Distal myopathy	Click to Show/Hide
The Studied Tissue	Muscle tissue
The Specified Disease	Tibial muscular dystrophy [ICD-11:8C75]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.00E-03; Fold-change: 1.34E-01; Z-score: 1.10E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 09	Visual system disease	Click to Show/Hide
ICD-11: 9A96	Anterior uveitis	Click to Show/Hide
The Studied Tissue	Peripheral monocyte
The Specified Disease	Autoimmune uveitis [ICD-11:9A96]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.34E-02; Fold-change: -9.83E-02; Z-score: -5.71E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 11	Circulatory system disease	Click to Show/Hide
ICD-11: BA41	Myocardial infarction	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Myocardial infarction [ICD-11:BA41-BA50]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.35E-02; Fold-change: 1.96E-01; Z-score: 4.18E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: BA80	Coronary artery disease	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Coronary artery disease [ICD-11:BA80-BA8Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.83E-01; Fold-change: -8.91E-02; Z-score: -4.03E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: BB70	Aortic valve stenosis	Click to Show/Hide
The Studied Tissue	Calcified aortic valve
The Specified Disease	Aortic stenosis [ICD-11:BB70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.75E-01; Fold-change: -7.15E-02; Z-score: -1.02E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 12	Respiratory system disease	Click to Show/Hide
ICD-11: 7A40	Central sleep apnoea	Click to Show/Hide
The Studied Tissue	Hyperplastic tonsil
The Specified Disease	Apnea [ICD-11:7A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.67E-01; Fold-change: 7.68E-02; Z-score: 2.20E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA08	Vasomotor or allergic rhinitis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Olive pollen allergy [ICD-11:CA08.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.52E-02; Fold-change: 8.13E-02; Z-score: 6.76E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA0A	Chronic rhinosinusitis	Click to Show/Hide
The Studied Tissue	Sinus mucosa tissue
The Specified Disease	Chronic rhinosinusitis [ICD-11:CA0A]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.03E-01; Fold-change: 9.55E-02; Z-score: 9.27E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA22	Chronic obstructive pulmonary disease	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.79E-03; Fold-change: 1.32E-01; Z-score: 7.85E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Small airway epithelium
The Specified Disease	Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.82E-01; Fold-change: -1.71E-02; Z-score: -9.86E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA23	Asthma	Click to Show/Hide
The Studied Tissue	Nasal and bronchial airway
The Specified Disease	Asthma [ICD-11:CA23]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.65E-02; Fold-change: -4.37E-02; Z-score: -7.84E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CB03	Idiopathic interstitial pneumonitis	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Idiopathic pulmonary fibrosis [ICD-11:CB03.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.67E-01; Fold-change: -4.03E-02; Z-score: -2.13E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 13	Digestive system disease	Click to Show/Hide
ICD-11: DA0C	Periodontal disease	Click to Show/Hide
The Studied Tissue	Gingival tissue
The Specified Disease	Periodontal disease [ICD-11:DA0C]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 8.60E-05; Fold-change: -2.42E-01; Z-score: -6.58E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: DA42	Gastritis	Click to Show/Hide
The Studied Tissue	Gastric antrum tissue
The Specified Disease	Eosinophilic gastritis [ICD-11:DA42.2]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 5.67E-01; Fold-change: -7.14E-03; Z-score: -9.59E-03
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: DB92	Non-alcoholic fatty liver disease	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Non-alcoholic fatty liver disease [ICD-11:DB92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.49E-01; Fold-change: 6.65E-01; Z-score: 5.19E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: DB99	Hepatic failure	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Liver failure [ICD-11:DB99.7-DB99.8]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.11E-04; Fold-change: -2.33E+00; Z-score: -2.27E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: DD71	Ulcerative colitis	Click to Show/Hide
The Studied Tissue	Colon mucosal tissue
The Specified Disease	Ulcerative colitis [ICD-11:DD71]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 8.61E-02; Fold-change: 1.23E-01; Z-score: 6.11E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
ICD-11: DD91	Irritable bowel syndrome	Click to Show/Hide
The Studied Tissue	Rectal colon tissue
The Specified Disease	Irritable bowel syndrome [ICD-11:DD91.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.16E-02; Fold-change: 2.13E-01; Z-score: 4.28E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 14	Skin disease	Click to Show/Hide
ICD-11: EA80	Atopic eczema	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Atopic dermatitis [ICD-11:EA80]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.18E-02; Fold-change: 5.11E-02; Z-score: 3.21E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: EA90	Psoriasis	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Psoriasis [ICD-11:EA90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.39E-04; Fold-change: -1.32E-01; Z-score: -4.10E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.45E-17; Fold-change: 3.46E-01; Z-score: 1.40E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: ED63	Acquired hypomelanotic disorder	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Vitiligo [ICD-11:ED63.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.37E-01; Fold-change: 0.00E+00; Z-score: 0.00E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: ED70	Alopecia or hair loss	Click to Show/Hide
The Studied Tissue	Skin from scalp
The Specified Disease	Alopecia [ICD-11:ED70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.43E-01; Fold-change: 5.42E-02; Z-score: 1.47E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: EK0Z	Contact dermatitis	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Sensitive skin [ICD-11:EK0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.28E-01; Fold-change: -2.95E-02; Z-score: -1.87E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 15	Musculoskeletal system/connective tissue disease	Click to Show/Hide
ICD-11: FA00	Osteoarthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Arthropathy [ICD-11:FA00-FA5Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.76E-01; Fold-change: -7.97E-02; Z-score: -6.68E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Synovial tissue
The Specified Disease	Osteoarthritis [ICD-11:FA00-FA0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.17E-01; Fold-change: -3.87E-02; Z-score: -3.88E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA20	Rheumatoid arthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Childhood onset rheumatic disease [ICD-11:FA20.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.63E-01; Fold-change: -1.26E-02; Z-score: -9.04E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Synovial tissue
The Specified Disease	Rheumatoid arthritis [ICD-11:FA20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.48E-01; Fold-change: 1.12E-01; Z-score: 7.24E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA24	Juvenile idiopathic arthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Juvenile idiopathic arthritis [ICD-11:FA24]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.42E-01; Fold-change: 3.89E-02; Z-score: 1.18E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA92	Inflammatory spondyloarthritis	Click to Show/Hide
The Studied Tissue	Pheripheral blood
The Specified Disease	Ankylosing spondylitis [ICD-11:FA92.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.27E-01; Fold-change: -2.63E-02; Z-score: -1.68E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FB83	Low bone mass disorder	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Osteoporosis [ICD-11:FB83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.44E-01; Fold-change: 1.29E-03; Z-score: 1.52E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 16	Genitourinary system disease	Click to Show/Hide
ICD-11: GA10	Endometriosis	Click to Show/Hide
The Studied Tissue	Endometrium tissue
The Specified Disease	Endometriosis [ICD-11:GA10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.02E-01; Fold-change: 2.47E-01; Z-score: 6.15E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: GC00	Cystitis	Click to Show/Hide
The Studied Tissue	Bladder tissue
The Specified Disease	Interstitial cystitis [ICD-11:GC00.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.53E-02; Fold-change: -2.16E-01; Z-score: -2.35E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 19	Condition originating in perinatal period	Click to Show/Hide
ICD-11: KA21	Short gestation disorder	Click to Show/Hide
The Studied Tissue	Myometrium
The Specified Disease	Preterm birth [ICD-11:KA21.4Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.12E-01; Fold-change: -4.32E-02; Z-score: -2.58E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 20	Developmental anomaly	Click to Show/Hide
ICD-11: LD2C	Overgrowth syndrome	Click to Show/Hide
The Studied Tissue	Adipose tissue
The Specified Disease	Simpson golabi behmel syndrome [ICD-11:LD2C]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.71E-01; Fold-change: 0.00E+00; Z-score: 0.00E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: LD2D	Phakomatoses/hamartoneoplastic syndrome	Click to Show/Hide
The Studied Tissue	Perituberal tissue
The Specified Disease	Tuberous sclerosis complex [ICD-11:LD2D.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.07E-01; Fold-change: 8.50E-02; Z-score: 9.43E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual

References
1	Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
2	DrugBank(Pharmacology-Metabolism)Bupropion
3	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
4	Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation
5	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
6	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
7	DrugBank(Pharmacology-Metabolism)Estrone
8	Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects
9	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
10	Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar;26(3):275-84.
11	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
12	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
13	FDA LABEL:Hydrocodone
14	Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry
15	Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects
16	In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
17	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
18	DrugBank(Pharmacology-Metabolism):Almogran
19	U. S. FDA Label -Almogran
20	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
21	Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol Drug Metab Dispos. 2021 Oct;49(10):882-891. doi: 10.1124/dmd.120.000350.
22	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
23	Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017 May;18(7):601-605.
24	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
25	The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
26	Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults. Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w.
27	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
28	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
29	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
30	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
31	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
32	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
33	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
34	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
35	The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol. 2001 Dec;21(6):549-55.
36	Drug Interactions Flockhart Table
37	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
38	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
39	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
40	Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
41	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites
42	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
43	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
44	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
45	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
46	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
47	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
48	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
49	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
50	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
51	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
52	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
53	FDA Approved Drug Products: Perforomist? inhalation solution
54	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
55	Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9.
56	In?vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
57	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
58	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
59	Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015 May;55(5):563-72.
60	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
61	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
62	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
63	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
64	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
65	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
66	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
67	Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood Epilepsia. 1995 Mar;36(3):241-8. doi: 10.1111/j.1528-1157.1995.tb00991.x.
68	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
69	A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4.
70	Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.
71	Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90.
72	Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
73	In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab Dispos. 2003 Oct;31(10):1240-50. doi: 10.1124/dmd.31.10.1240.
74	Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549.
75	Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
76	Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
77	In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite Drug Metab Dispos. 2011 Apr;39(4):693-702. doi: 10.1124/dmd.110.036004.
78	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects Drug Metab Rev. 2017 Nov;49(4):451-463. doi: 10.1080/03602532.2017.1377223.
79	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635.
80	Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016 Dec 27;61(1).
81	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
82	Suvorexant: a promising, novel treatment for insomnia Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5. doi: 10.2147/NDT.S31495.
83	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes Drug Metab Lett. 2008 Jan;2(1):67-75. doi: 10.2174/187231208783478434.
84	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
85	Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP
86	Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
87	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
88	Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
89	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
90	Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
91	Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers
92	Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5.
93	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
94	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.
95	Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
96	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
97	Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
98	Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
99	CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7.
100	Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80.
101	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
102	A dual system platform for drug metabolism: Nalbuphine as a model compound
103	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
104	Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
105	CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
106	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
107	Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients Ann Clin Biochem. 2018 May;55(3):385-393. doi: 10.1177/0004563217731432.
108	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
109	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
110	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
111	Metabolism of sumatriptan revisited
112	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist J Clin Pharmacol. 2015 Sep;55(9):1004-11. doi: 10.1002/jcph.507.
113	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
114	Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells
115	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
116	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
117	Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
118	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
119	More methemoglobin is produced by benzocaine treatment than lidocaine treatment in human in vitro systems
120	A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement Drug Metab Dispos. 2015 Apr;43(4):523-33. doi: 10.1124/dmd.114.062620.
121	Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66.
122	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
123	The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
124	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review Curr Neuropharmacol. 2016;14(2):191-9. doi: 10.2174/1570159x14666151117122458.
125	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
126	The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes
127	Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br J Clin Pharmacol. 2015 Aug;80(2):267-75.
128	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460.
129	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
130	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
131	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
132	Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
133	PubChem:Tapinarof
134	Lerman J. (2014). Neonatal Anesthesia. Springer.
135	Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
136	CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000 Mar;28(3):354-9.
137	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
138	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
139	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
140	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
141	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
142	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
143	Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
144	Lithium Intoxication in the Elderly: A Possible Interaction between Azilsartan, Fluvoxamine, and Lithium
145	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C191/CYP2C192 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
146	Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
147	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
148	Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
149	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
150	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes Xenobiotica. 2016 Oct;46(10):868-74. doi: 10.3109/00498254.2015.1134852.
151	Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
152	Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
153	Flibanserin therapy and CYP2C19 genotype.
154	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
155	Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.
156	Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2016 Jan;56(1):47-55.
157	Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
158	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
159	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
160	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
161	Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 Apr;24(2):87-92.
162	In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
163	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
164	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
165	Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48.
166	FDA Label of Diacomit. The 2020 official website of the U.S. Food and Drug Administration.
167	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
168	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
169	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
170	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
171	Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters Curr Drug Metab. 2020;21(14):1127-1135. doi: 10.2174/1389200221999201208211537.
172	The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
173	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
174	Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760.
175	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
176	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
177	Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
178	Cross-species comparisons of the pharmacokinetics of ibudilast
179	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
180	Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
181	In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 Aug;23(4):247-55.
182	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
183	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
184	Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005 Jan;28(1):124-9.
185	In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6
186	Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002 Apr;66(2):185-200.
187	In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702.
188	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
189	Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
190	Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450
191	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
192	CYP2D plays a major role in berberine metabolism in liver of mice and humans
193	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
194	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
195	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
196	No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine
197	Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6.
198	The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):447-50.
199	Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30.
200	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
201	The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
202	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
203	Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012 Jun;97(6):569-72.
204	Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44.
205	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
206	Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull. 2002 Feb;25(2):235-8.
207	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
208	The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol. 2003 Apr;23(2):169-75.
209	The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study. Eur J Med Chem. 2009 Feb;44(2):854-61.
210	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
211	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
212	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
213	Urinary diazepam metabolite distribution in a chronic pain population J Anal Toxicol. 2014 Apr;38(3):135-42. doi: 10.1093/jat/bku001.
214	DrugBank(Pharmacology-Metabolism)Lofexidine
215	Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride Drug Metab Dispos. 2012 Sep;40(9):1723-35. doi: 10.1124/dmd.112.045120.
216	FDA LABEL:Milnacipran
217	Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol. 2002 Nov;58(8):543-5.
218	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
219	Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
220	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
221	Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
222	Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens
223	Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects
224	Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019;20(2):147-154.
225	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
226	Australian Public Assessment Report for asunaprevir.
227	Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib
228	DrugBank(Pharmacology-Metabolism):Mavacamten
229	Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
230	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
231	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
232	In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
233	Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans
234	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
235	DrugBank(Pharmacology-Metabolism):Ganaxolone
236	Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017 Feb 20;2(1):2-10.
237	DrugBank(Pharmacology-Metabolism):PT2977
238	DrugBank(Pharmacology-Metabolism):Ag-221
239	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
240	A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
241	Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies
242	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
243	The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
244	Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans
245	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
246	Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2 Inhibitor PT2385 In Vivo and In Vitro
247	Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies
248	In vitro inhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight into in vitro and in vivo discrepancy of metabolite formation in humans
249	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
250	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
251	Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638
252	Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
253	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
254	Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells
255	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
256	In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles
257	Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
258	Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats
259	Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer
260	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
261	Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling
262	In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor
263	Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D(2)/D(3) receptor antagonist for gastroparesis, towards cytochrome P450s and transporters
264	Metabolic map and bioactivation of the anti-tumour drug noscapine
265	The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects
266	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
267	Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation
268	Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species
269	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
270	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes
271	Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor
272	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
273	An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
274	Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans
275	In vitro metabolism of 7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite
276	Identification of cytochrome P450 isoform involved in the metabolism of YM992, a novel selective serotonin re-uptake inhibitor, in human liver microsomes
277	Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells. Antimicrob Agents Chemother. 2005 May;49(5):2044-9. doi: 10.1128/AAC.49.5.2044-2049.2005.
278	Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide
279	Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor
280	In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450
281	In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism
282	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
283	A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.
284	Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
285	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
286	Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
287	Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Chirality. 2007 Jul;19(7):550-8.
288	The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6
289	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
290	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
291	Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
292	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
293	A cytochrome P450 class I electron transfer system from Novosphingobium aromaticivorans. Appl Microbiol Biotechnol. 2010 Mar;86(1):163-75.
294	Study on the cytochrome P450-mediated oxidative metabolism of the terpene alcohol linalool: indication of biological epoxidation
295	Metabolism of geraniol and linalool in the rat and effects on liver and lung microsomal enzymes
296	Active cyamemazine metabolites in patients treated with cyamemazine (Tercian?): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET)
297	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
298	Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999 Dec;66(6):642-6.
299	Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes?
300	High-performance liquid chromatographic determination of seratrodast and its metabolites in human serum and urine
301	U. S. FDA Label - Acebutolol
302	Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches Biochem Pharmacol. 2016 Jun 1;109:70-82. doi: 10.1016/j.bcp.2016.03.020.
303	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
304	Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009 Jun;49(6):719-24.
305	Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
306	CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies
307	Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype
308	Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
309	Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16.
310	Genetic toxicology and toxicokinetics of arecoline and related areca nut compounds: an updated review
311	A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: application to the characterization of the metabolic profile and stability of formoterol in urine
312	Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation Drug Metab Dispos. 1999 Oct;27(10):1104-16.
313	Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?
314	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4.
315	In Vitro Kinetic Characterization of Axitinib Metabolism
316	The metabolism of berberine and its contribution to the pharmacological effects
317	LABEL: JUXTAPID- lomitapide mesylate capsule
318	Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection Drug Metab Dispos. 2006 Mar;34(3):427-39. doi: 10.1124/dmd.105.007617.
319	Metabolic disposition of 14C-bromfenac in healthy male volunteers J Clin Pharmacol. 1998 Aug;38(8):744-52. doi: 10.1002/j.1552-4604.1998.tb04815.x.
320	Structural elucidation of phase I and II metabolites of bupivacaine in horse urine and fungi of the Cunninghamella species using liquid chromatography/multi-stage mass spectrometry Rapid Commun Mass Spectrom. 2012 Jun 15;26(11):1338-46. doi: 10.1002/rcm.6225.
321	Abuse Potential of Soma: the GABA(A) Receptor as a Target Mol Cell Pharmacol. 2009 Jan 1;1(4):180-186.
322	Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography J Pharm Biomed Anal. 2001 Jan;24(3):381-9. doi: 10.1016/s0731-7085(00)00426-x.
323	Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol Drug Metab Dispos. 2007 Oct;35(10):1730-2. doi: 10.1124/dmd.107.016758.
324	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
325	Analytical methodologies for the enantiodetermination of citalopram and its metabolites
326	Kinetics and metabolism of clobazam in animals and man
327	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
328	Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
329	Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation
330	Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation
331	The KEGG resource for deciphering the genome
332	In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165.
333	Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics. 2004 Aug;14(8):549-56.
334	Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32.
335	Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People Eur J Drug Metab Pharmacokinet. 2020 Aug;45(4):477-485. doi: 10.1007/s13318-020-00614-8.
336	Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants. Drugs R D. 2022 Mar;22(1):43-50. doi: 10.1007/s40268-021-00375-y.
337	Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. J Vet Pharmacol Ther. 2021 Sep;44(5):733-744. doi: 10.1111/jvp.12991.
338	DrugBank(Pharmacology-Metabolism)Diazepam
339	Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis Eur J Clin Pharmacol. 1983;25(3):389-94. doi: 10.1007/BF01037953.
340	Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection J Chromatogr. 1981 Nov 6;217:263-71. doi: 10.1016/s0021-9673(00)88081-4.
341	Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
342	Bioconcentration, metabolism and effects of diphenhydramine on behavioral and biochemical markers in crucian carp (Carassius auratus) Sci Total Environ. 2016 Feb 15;544:400-9. doi: 10.1016/j.scitotenv.2015.11.132.
343	Non-invasive skin sampling detects systemically administered drugs in humans. PLoS One. 2022 Jul 26;17(7):e0271794. doi: 10.1371/journal.pone.0271794.
344	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
345	Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids
346	Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions
347	#N/A
348	FDA:Enasidenib
349	Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram Drug Metab Dispos. 2001 Aug;29(8):1102-9.
350	Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro Drug Metab Dispos. 2009 Dec;37(12):2340-8. doi: 10.1124/dmd.109.029355.
351	Expression, activity and regulation of CYP3A in human and rodent brain Drug Metab Rev. 2008;40(1):149-68. doi: 10.1080/03602530701836712.
352	Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole Clin Pharmacokinet. 2001;40(6):411-26. doi: 10.2165/00003088-200140060-00003.
353	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
354	Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
355	Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561-74.
356	LABEL:INREBIC- fedratinib hydrochloride capsule
357	Felbamate-induced apoptosis of hematopoietic cells is mediated by redox-sensitive and redox-independent pathways Epilepsy Res. 2002 Jan;48(1-2):57-69. doi: 10.1016/s0920-1211(01)00320-5.
358	U. S. FDA Label -Fenfluramine
359	LABEL:DDYI- flibanserin tablet, film coated
360	Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):460-5.
361	Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica. 1999 Oct;29(10):973-86.
362	Lack of interaction of buprenorphine with flunitrazepam metabolism
363	DrugBank(Pharmacology-Metabolism):Fluoxetine hydrochloride
364	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
365	Simultaneous identification and quantitation of fluoxetine and its metabolite, norfluoxetine, in biological samples by GC-MS
366	O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11.
367	Esophageal bezoar due to karaya gum granules used as a laxative
368	Ganaxolone
369	Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon
370	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
371	Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons
372	The metabolism of gliclazide in man
373	Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human
374	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
375	DrugBank(Pharmacology-Metabolism):Hydrocodone bitartrate
376	Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism
377	Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans Biochem Pharmacol. 2013 Apr 15;85(8):1195-202. doi: 10.1016/j.bcp.2013.01.031.
378	PubChem : JNJ-54135419
379	Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration Eur J Drug Metab Pharmacokinet. 2012 Dec;37(4):241-8. doi: 10.1007/s13318-012-0093-x.
380	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
381	The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
382	#N/A
383	Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan
384	In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
385	Meperidine and normeperidine levels following meperidine administration during labor. I. Mother
386	Effects of ethinyl estradiol on pharmacokinetics of meperidine and pentobarbital in the rat
387	Quantification of mephenytoin and its metabolites 4'-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method
388	Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
389	Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies
390	Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil J Cardiovasc Pharmacol. 1991 Dec;18(6):918-25. doi: 10.1097/00005344-199112000-00020.
391	Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients Br J Clin Pharmacol. 2008 Apr;65(4):548-57. doi: 10.1111/j.1365-2125.2007.03039.x.
392	Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor Mol Pharmacol. 2021 Mar;99(3):184-196. doi: 10.1124/molpharm.120.000116.
393	Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
394	Neutrophil- and myeloperoxidase-mediated metabolism of reduced nimesulide: evidence for bioactivation Chem Res Toxicol. 2010 Nov 15;23(11):1691-700. doi: 10.1021/tx1001496.
395	Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline J Clin Pharmacol. 2019 Apr;59(4):532-540. doi: 10.1002/jcph.1344.
396	DrugBank(Pharmacology-Metabolism)Nortriptyline hydrochloride
397	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
398	Anti-Parkinson's disease drugs and pharmacogenetic considerations Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):859-74. doi: 10.1517/17425255.2013.789018.
399	Validation of enantioseparation and quantitation of an active metabolite of abrocitinib in human plasma
400	The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans
401	Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men
402	Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review J Psychiatry Neurosci. 1992 Nov;17(5):206-14.
403	DrugBank(Pharmacology-Metabolism)Phenobarbital
404	Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom. 2007;21(2):169-79. doi: 10.1002/rcm.2813.
405	Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions. Pharmacol Rep. 2023 Apr;75(2):423-441. doi: 10.1007/s43440-023-00447-7.
406	Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2023 Jan;12(1):21-29. doi: 10.1002/cpdd.1172.
407	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
408	Prazepam metabolism by man Clin Pharmacol Ther. 1970 Nov-Dec;11(6):890-7. doi: 10.1002/cpt1970116890.
409	Prazepam metabolites in dog urine J Pharm Sci. 1970 Mar;59(3):322-5. doi: 10.1002/jps.2600590309.
410	In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel Pharmacol Res Perspect. 2020 Aug;8(4):e00618. doi: 10.1002/prp2.618.
411	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006 Sep-Oct;63(5):381-5.
412	Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice Drug Metab Dispos. 1998 Jun;26(6):585-94.
413	Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):255-64. doi: 10.1007/BF03190029.
414	Managing the Drug-Drug Interaction With Apixaban and Primidone: A Case Report. Hosp Pharm. 2023 Aug;58(4):345-349. doi: 10.1177/00185787221150928.
415	Ticagrelor and primidone interaction masquerading as dual antiplatelet therapy noncompliance. Future Cardiol. 2023 Jun 14. doi: 10.2217/fca-2023-0011.
416	Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry Biomed Chromatogr. 2012 Jun;26(6):754-60. doi: 10.1002/bmc.1725.
417	Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route J Clin Pharmacol. 2005 Dec;45(12):1383-90. doi: 10.1177/0091270005281044.
418	In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):747-52.
419	Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography-mass spectrometry
420	Single dose pharmacokinetics of proguanil and its metabolites in pregnancy
421	FDA label:Belzutifan
422	CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever
423	Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction
424	Biotransformation of moclobemide in humans
425	Simultaneous Determination of Rosuvastatin, Rosuvastatin-5?S-lactone, and N-desmethyl Rosuvastatin in Human Plasma by UPLC-MS/MS and Its Application to Clinical Study
426	Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects
427	A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers
428	DrugBank(Pharmacology-Metabolism)Sertraline hydrochloride
429	Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
430	Pharmacogenetic Testing and Therapeutic Drug Monitoring Of Sertraline at a Residential Treatment Center for Children and Adolescents: A Pilot Study. Innov Pharm. 2022 Dec 26;13(4):10.24926/iip.v13i4.5035. doi: 10.24926/iip.v13i4.5035.
431	Sertraline. 2022 May 15. Drugs and Lactation Database (LactMed?) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006C.
432	Neonicotinoids and pharmaceuticals in hair of the Red fox (Vulpes vulpes) from the Cavallino-Treporti peninsula, Italy. Environ Res. 2023 Jul 1;228:115837. doi: 10.1016/j.envres.2023.115837.
433	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
434	Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x.
435	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
436	Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity
437	Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5.
438	CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens Forensic Sci Int. 2020 Jul;312:110307. doi: 10.1016/j.forsciint.2020.110307.
439	In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans Xenobiotica. 2016 Oct;46(10):882-95. doi: 10.3109/00498254.2015.1129565.
440	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
441	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
442	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
443	Identification and biological activity of tamoxifen metabolites in human serum Biochem Pharmacol. 1983 Jul 1;32(13):2045-52. doi: 10.1016/0006-2952(83)90425-2.
444	PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.
445	The tamoxifen dilemma. Carcinogenesis. 1999 Jul;20(7):1153-60.
446	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
447	LABEL:UCYNTA- tapentadol hydrochloride tablet, film coated
448	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
449	Pharmacokinetics and metabolism of temazepam in man and several animal species Br J Clin Pharmacol. 1979;8(1):23S-29S. doi: 10.1111/j.1365-2125.1979.tb00451.x.
450	Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.
451	Drug Interactions Flockhart Table:Docetaxel
452	A multi-residue chiral liquid chromatography coupled with tandem mass spectrometry method for analysis of antifungal agents and their metabolites in aqueous environmental matrices. Anal Methods. 2021 Jun 14;13(22):2466-2477. doi: 10.1039/d1ay00556a.
453	Thalidomide metabolism and hydrolysis: mechanisms and implications
454	Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine
455	Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007 Jul;35(7):1135-41.
456	Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8.
457	Total determination of triclabendazole and its metabolites in bovine tissues using liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:54-59. doi: 10.1016/j.jchromb.2019.01.021.
458	Egaten FDA label
459	Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996 Feb;41(2):149-56.
460	Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers
461	Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays
462	DETERMINATION OF VENLAFAXINE, VILAZODONE AND THEIR MAIN ACTIVE METABOLITES IN HUMAN SERUM BY HPLC-DAD AND HPLC-MS
463	Assessments of CYP?inhibition?based drug-drug interaction between vonoprazan and poziotinib in?vitro and in?vivo
464	Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
465	The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
466	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
467	FDA Approved Drug Products:Oxbryta (voxelotor) tablets
468	Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.
469	BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification
470	Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis
471	Zolpidem urine excretion profiles and cross-reactivity with ELISA(?) kits in subjects using Zolpidem or Ambien(?) CR as a prescription sleep aid
472	Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.